

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

10/510912

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 03/089672 A1

(51) International Patent Classification⁷: C12Q 1/70,
G01N 33/53, C12N 9/00, C07H 21/02, 21/04

Avenue, Rahway, NJ 07065-0907 (US). **MURRAY, Edward, M.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **ZUCK, Paul, D.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(21) International Application Number: PCT/US03/12509

(22) International Filing Date: 11 April 2003 (11.04.2003)

(74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(25) Filing Language: English

(81) Designated States (*national*): CA, JP, US.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(30) Priority Data:
60/372,847 16 April 2002 (16.04.2002) US

Published:

(71) Applicant (*for all designated States except US*): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FLORES, Osvaldo, A.** [CL/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **GROBLER, Jay** [US/US]; 126 East Lincoln

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HEPATITIS C VIRUS ASSAY SYSTEMS

(57) Abstract: The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a 3' UTR based on the HCV-1a 3' UTR. These features can be employed alone or together, and are preferably combined together to measure HCV replicon activity and the affect of compounds on such activity

BEST AVAILABLE COPY

570,912



WO 03/089672 A1

TITLE OF THE INVENTION
HEPATITIS C VIRUS ASSAY SYSTEMS

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 The present application claims priority to provisional application U.S. Serial No. 60/372,847, filed April 16, 2002, hereby incorporated by reference herein.

BACKGROUND OF THE INVENTION

- 10 The references cited in the present application are not admitted to be prior art to the claimed invention.

- It is estimated that about 3% of the world's population are infected with the Hepatitis C virus (HCV). (Wasley, *et al.*, 2000. *Semin. Liver Dis.* 20, 1-16.) Exposure to HCV results in an overt acute disease in a small percentage of cases, while in most instances the virus establishes a chronic infection causing liver
15 inflammation and slowly progresses into liver failure and cirrhosis. (Iwarson, 1994. *FEMS Microbiol. Rev.* 14, 201-204.) In addition, epidemiological surveys indicate an important role of HCV in the pathogenesis of hepatocellular carcinoma. (Kew, 1994. *FEMS Microbiol. Rev.* 14, 211-220, Alter, 1995. *Blood* 85, 1681-1695.)

- The HCV genome consists of a single strand RNA of about 9.5 kb in
20 length, encoding a precursor polyprotein of about 3000 amino acids. (Choo, *et al.*, 1989. *Science* 244, 362-364, Choo, *et al.*, 1989. *Science* 244, 359-362, Takamizawa, *et al.*, 1991. *J. Virol.* 65, 1105-1113.) The HCV polyprotein contains the viral proteins in the order: C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B.

- Individual viral proteins are produced by proteolysis of the HCV
25 polyprotein. Host cell proteases release the putative structural proteins C, E1, E2, and p7, and create the N-terminus of NS2 at amino acid 810. (Mizushima, *et al.*, 1994. *J. Virol.* 68, 2731-2734, Hijikata, *et al.*, 1993. *P.N.A.S. USA* 90, 10773-10777.)

- The non-structural proteins NS3, NS4A, NS4B, NS5A and NS5B
30 presumably form the virus replication machinery and are released from the polyprotein. A zinc-dependent protease associated with NS2 and the N-terminus of NS3 is responsible for cleavage between NS2 and NS3. (Grakoui, *et al.*, 1993. *J. Virol.* 67, 1385-1395, Hijikata, *et al.*, 1993. *P.N.A.S. USA* 90, 10773-10777.)

- A distinct serine protease located in the N-terminal domain of NS3 is responsible for proteolytic cleavages at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A
35 and NS5A/NS5B junctions. (Barthenschlager, *et al.*, 1993. *J. Virol.* 67, 3835-3844,

Grakoui, *et al.*, 1993. *Proc. Natl. Acad. Sci. USA* 90, 10583-10587, Tomei, *et al.*, 1993. *J. Virol.* 67, 4017-4026.) RNA stimulated NTPase and helicase activities are located in the C-terminal domain of NS3.

NS4A provides a cofactor for NS3 protease activity. (Failla, *et al.*, *J. Virol.* 1994. 68, 3753-3760, De Francesco, *et al.*, U.S. Patent No. 5,739,002.)

NS5A is a highly phosphorylated protein conferring interferon resistance. (De Francesco, *et al.*, 2000. *Semin Liver Dis.*, 20(1), 69-83, Pawlotsky, 1999. *J. Viral Hepat. Suppl.* 1, 47-48.)

NS5B provides an RNA-dependent RNA polymerase. (De Francesco, *et al.*, International Publication Number WO 96/37619, Behrens, *et al.*, 1996. *EMBO* 15, 12-22, Lohmann, *et al.*, 1998. *Virology* 249, 108-118.)

SUMMARY OF THE INVENTION

The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a 3' UTR based on the HCV-1a 3' UTR. These features can be employed alone or together, and are preferably combined together to measure HCV replicon activity and the affect of compounds on such activity.

Thus, a first aspect of the present invention describes a method of measuring the ability of a compound to alter HCV replicon activity using a screening cell line comprising a first HCV replicon and a second HCV replicon. The first replicon comprises a selection sequence. The second replicon comprises a nucleotide sequence encoding for beta-lactamase. The method is performed using conditions supporting beta-lactamase activity. Such conditions provide the proper environment for beta-lactamase activity and include factors such as proper pH, temperature and buffer.

A selection sequence facilitates identification or isolation of cells containing the sequence. Examples of selection sequences include sequences encoding drug resistance and reporters compatible with cell sorting.

Another aspect of the present invention describes an HCV replicon enhanced cell comprising a first HCV replicon and a second HCV replicon. The first replicon comprises a selection sequence and is present in an amount compatible with replication of the second replicon. The second replicon is different from the first replicon and preferably encodes a reporter.

Another aspect of the present invention describes a method of producing an HCV replicon enhanced cell. The method comprises the steps of: (a) introducing into a cell a HCV replicon comprising a selection sequence; (b) obtaining a replicon enhanced cell; and (c) introducing into the replicon enhanced cell a replicon comprising a reporter.

Another aspect of the present invention describes an HCV replicon comprising a beta-lactamase reporter. In this aspect, the replicon does not contain a sequence coding for resistance to an agent that inhibits cell growth.

Another aspect of the present invention describes a chimeric HCV replicon containing an HCV-1a 3' UTR. The chimeric replicon contains one or more HCV regions from different HCV strains. Reference to strains includes subtypes, which may be clinical isolates. Examples of chimeric replicons include replicons formed from one or more strains classified as HCV-1a, where the replicon contains a 3' UTR from one strain and one or more HCV regions from a different strain(s); and the replicon being formed from two or more HCV strains classified in different groups, where the replicon contains a 3' HCV-1a UTR.

Preferably, the chimeric replicon contains the HCV-1a 3'UTR provided by bases 8407-8641 of SEQ. ID. NO. 1. The remainder of such a chimeric replicon contains one or more HCV regions, preferably a non-structural region, from a HCV strain not containing the HCV-1a 3' UTR provided by SEQ. ID. NO. 1.

Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1D illustrate the HCV replicon of SEQ. ID. NO. 1. Sequences of all non-structural proteins are derived from con1. The approximate location of different regions of SEQ. ID. NO. 1 are as follows:

- 1-341: 5'-nontranslated region
- 342-1178: HCV core – β -lactamase fusion protein
- 1225-1800: EMCV IRES
- 1801-2451: NS2

- 2452-4344: NS3
- 4345-4506: NS4A
- 4507-5289: NS4B
- 5290-6630: NS5A
- 5 6631-8406: NS5B
- 8407-8641: HCV(1a) 3'-nontranslated region
- 8642-8732: Hepatitis delta ribozyme.

Figures 2A-2D illustrate the HCV replicon of SEQ. ID. NO. 2.

- Sequences of all non-structural proteins are derived from con1. The approximate
 10 location of different regions of SEQ. ID. NO. 2 are as follows:

- 1-341: 5'-nontranslated region
- 342-1178: HCV core – β -lactamase fusion protein
- 1225-1800: EMCV IRES
- 1801-3696: NS3
- 15 3697-3858: NS4A
- 3859-4641: NS4B
- 4642-5982: NS5A
- 5983-7755: NS5B
- 5991-5996: BstZ17I restriction site
- 20 7751-7756: Cla I restriction site
- 7756-7993: HCV(1a) 3'-nontranslated region
- 7994-8085: Hepatitis delta ribozyme.

- Figures 3A and 3B provide schematic diagrams of replicons of SEQ. ID. NO. 1 and SEQ. ID. NO. 2. Both replicons are derived from HCV con1 and
 25 contain the S2204I adaptive mutation in NS5A. An HCV genotype 1a 3'-UTR is present in both clones, and both have a hepatitis delta ribozyme that is autocleaved to yield native 3'-ends. (A) Structure of the replicon SEQ. ID. NO.1 which encodes NS2 through NS5B. (B) Structure of replicon SEQ. ID. NO. 2. which encodes NS3 through NS5B. The replicon of SEQ. ID. NO. 2 contains unique BstZ17 I and Cla I
 30 restriction sites at the 5' and 3' ends of the NS5B coding region, respectively, to facilitate subcloning of NS5B sequences for resistance phenotyping.

Figure 4 illustrates quantitation of replicon RNA in different cell lines. Replicon RNA was quantitated using strand specific RNase protection assays. Cellular GAPDH RNA and HCV replicon RNA of positive polarity are shown at the

top and lower panels respectively. The ratios of positive to negative strand replicon RNA in each cell line are indicated at the bottom of the figure.

Figure 5 illustrates stable maintenance of replicons harboring different adaptive mutations in partially cured JGEM cells.

Figure 6 illustrates persistence of beta-lactamase activity in the presence of inhibitor. The decay rates of beta-lactamase activity was measured in the presence of an NS5B inhibitor at 100% inhibitory dose (open symbols) either with (circles) or without (triangles) 0.5 μ M clavulanic acid. Closed symbols represent cells without NS5B inhibitor.

DETAILED DESCRIPTION OF THE INVENTION

The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a HCV-1a 3' UTR. These different features are preferably employed together to evaluate the ability of a compound to inhibit HCV replication.

Compounds inhibiting HCV replication have research and therapeutic applications. Research applications include the study of HCV and the production of replicon enhanced cells. Therapeutic applications include using those compounds having appropriate pharmacological properties such as efficacy and lack of unacceptable toxicity to treat or inhibit onset of HCV in a patient.

I. Beta-Lactamase Reporter Systems

Assays employing a beta-lactamase reporter system can be used to measure the activity of a nucleic acid or polypeptide coupled to a beta-lactamase and the effect of a compound on such activity. Nucleic acid coupled to a beta-lactamase contains a target nucleotide region and a region encoding a beta-lactamase. Beta-lactamase is the byproduct of target nucleic acid expression and measuring Bla activity provides a mean to measure target nucleic acid activity.

The target nucleotide region is a region of interest and can provide regulatory activities or encode for a polypeptide. Reference to polypeptide and polypeptide region does not provide a size limitation and includes smaller length polypeptides, enzymatic proteins, structural proteins, and polyproteins.

Activities that can be measured using a target nucleotide region and a region encoding a beta-lactamase include one or more of the following: target nucleotide region production, target nucleotide region processing, target nucleotide

region transport, activity of encoded for polypeptides involved in replication, and production of encoded for polypeptides. Nucleotide region transport includes extracellular transport that may be viral mediated.

5 A polypeptide coupled to beta-lactamase is a chimeric polypeptide containing a region of interest and a beta-lactamase. Polypeptide regions of interest include those providing enzymatic and structural proteins.

Polypeptide activities that can be measured using a beta-lactamase reporter system include one or more of the following: polypeptide production, polypeptide processing and polypeptide transport. Polypeptide transport includes
10 extracellular transport that may be viral mediated.

A preferred target nucleic acid is an HCV replicon. HCV replicons containing a region encoding a beta-lactamase can be used to measure the effect of a compound on both HCV nucleic acid and HCV protein activity. HCV proteins are involved in processing the HCV polyprotein and in HCV replication. Inhibiting HCV
15 proteins involved in HCV processing or more directly involved in HCV replication reduces the production of HCV replicons encoding beta-lactamase.

II. Beta-Lactamase Activity

Beta-lactamases are enzymes catalyzing the cleavage of the beta-
20 lactam ring present in cephalosporins. Different naturally occurring beta-lactamases and functionally derivatives of naturally occurring beta-lactamases are well known in the art. References such as Ambler, *Phil. Trans R. Soc. Lond. Ser. B.* 289:321-331, 1980, provide examples of naturally occurring β -lactamases.

Beta-lactamases that are functional derivatives of a naturally occurring
25 beta-lactamase can be produced by altering a naturally occurring sequence to produce an enzyme retaining beta-lactamase activity. Examples of common alterations include substitutions, deletions, and additions of amino acids or amino acid regions.

One method of designing altered proteins is to take into account amino acid R-groups. An amino acid R group affects different properties of the amino acid
30 such as physical size, charge, and hydrophobicity. Amino acids can be divided into different groups as follows: neutral and hydrophobic (alanine, valine, leucine, isoleucine, proline, tryptophan, phenylalanine, and methionine); neutral and polar (glycine, serine, threonine, tyrosine, cysteine, asparagine, and glutamine); basic (lysine, arginine, and histidine); and acidic (aspartic acid and glutamic acid).

Generally, in substituting different amino acids it is preferable to exchange amino acids having similar properties. Substituting different amino acids within a particular group, such as substituting valine for leucine, arginine for lysine, and asparagine for glutamine are good candidates for not causing a change in polypeptide functioning.

Changes outside of different amino acid groups can also be made. Preferably, such changes are made taking into account the position of the amino acid to be substituted in the polypeptide. For example, arginine can substitute more freely for nonpolar amino acids in the interior of a polypeptide than glutamate because of its long aliphatic side chain. (See, Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, Supplement 33 Appendix 1C.)

Derivatives can be produced to enhance intracellular activity. An example of such a derivative is TEM-1 beta-lactamase. (Kadonaga *et al.*, *J. Biol. Chem.* 259:2149-2154, 1984.) TEM-1 beta-lactamase is a derivative of *E. coli* beta-lactamase where the signal sequence is deleted. The deletion of the signal sequence increases cytoplasmic accumulation.

Beta-lactamase encoding sequences can be incorporated into nucleic acids taking into account the genetic code. The translation of a particular codon into a particular amino acid is well known in the art (see, *e.g.*, Lewin *GENES IV*, p. 119, Oxford University Press, 1990). Amino acids are encoded by codons as follows:

A=Ala=Alanine: codons GCA, GCC, GCG, GCU

C=Cys=Cysteine: codons UGC, UGU

D=Asp=Aspartic acid: codons GAC, GAU

E=Glu=Glutamic acid: codons GAA, GAG

F=Phe=Phenylalanine: codons UUC, UUU

G=Gly=Glycine: codons GGA, GGC, GGG, GGU

H=His=Histidine: codons CAC, CAU

I=Ile=Isoleucine: codons AUA, AUC, AUU

K=Lys=Lysine: codons AAA, AAG

L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU

M=Met=Methionine: codon AUG

N=Asn=Asparagine: codons AAC, AAU

P=Pro=Proline: codons CCA, CCC, CCG, CCU

Q=Gln=Glutamine: codons CAA, CAG

R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU

S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU

T=Thr=Threonine: codons ACA, ACC, ACG, ACU

V=Val=Valine: codons GUA, GUC, GUG, GUU

W=Trp=Tryptophan: codon UGG

5 Y=Tyr=Tyrosine: codons UAC, UAU.

III. Beta-Lactamase Assays

Intracellular beta-lactamase activity is preferably measured using a fluorogenic substrate that is cleaved by beta-lactamase. Preferred substrates are
10 membrane permeant fluorogenic substrates that become membrane impermeant inside a cell, and that are cleaved by beta-lactamase to produce a detectable signal. Examples of such substrates are provided in Zlokarnik, *et al.*, 1998. *Science* 279:84-88, and Tsien *et al.*, U.S. Patent No. 5,741,657.

In an embodiment of the present invention, a cell-permeant fluorescent
15 β -lactamase substrate such as CCF2-AM or CCF4-AM (Aurora Biosciences, Inc., San Diego, CA) is loaded into a cell. These substrates contain an ester group facilitating transport across the cell membrane. Inside the cell, the ester group is cleaved rendering the substrate membrane impermeant. The intact substrates when stimulated with light of ~405 nm, emit green fluorescence (~530 nm) due to resonant energy
20 transfer from a coumarin to fluorescein dye molecule. Cleavage of the substrate by beta-lactamase disrupts the resonance energy transfer and, the fluorescence emission changes to a blue color (~460 nm) of only the coumarin. The fluorescence emissions of the substrate present in the cells can be detected by, for example, fluorescence microscopy or by a fluorometer in conjunction with appropriate emission and
25 excitation filters.

IV. Use Of Beta-Lactamase Inhibitor

Beta-lactamase inhibitors such as clavulanic acid can be used to enhance a beta-lactamase reporter system by being present throughout the assay. For
30 example, clavulanic acid being present throughout an assay involving an HCV replicon beta-lactamase reporter sensitizes the assay towards HCV replication inhibitors.

Clavulanic acid can be used to enhance the signal-to-background ratio from the beta-lactamase reporter system wherein, a larger signal to noise ratio
35 facilitates detection of HCV replication inhibitors by better reflecting changes in the

intracellular concentration of beta-lactamase. Because clavulanic acid is an irreversible inhibitor, it is a more potent inhibitor of beta-lactamase at low enzyme concentrations than at high enzyme concentrations and therefore its inhibitory activity has a more pronounced effect in the background signal than in the foreground signal of the assay.

In different embodiments concerning the level of signal-to-background reduction, the beta-lactamase inhibitor is provided in an amount sufficient to enhance the signal-to-background ratio by 2 to 5 fold; the amount of inhibitor is about 10 nM to 1.0 μ M; and/or the inhibitor is an irreversible inhibitor, preferably clavulanic acid.

V. HCV Replicons

An HCV replicon is an RNA molecule able to autonomously replicate in a cultured cell and produce detectable levels of one or more HCV proteins. The HCV replicon expresses the HCV derived components of the replication machinery and contains cis-elements required for replication in a cultured cell.

The production and use of HCV replicons, and the effect of different mutations on replicon activity are described in different references. (See, for example, Lohmann, *et al.*, 1999. *Science* 285, 110-113, Bartenschlager, European Patent Application 1 043 399, published October 11, 2000, Blight, *et al.*, 2000. *Science* 290:1972-1974, Lohmann, *et al.*, 2001. *Journal of Virology* 75:1437-1449, and Pietschmann, *et al.*, 2001. *Journal of Virology* 75:1252-1264.)

The basic subunit of an HCV replicon encodes for a HCV NS3-NS4A-NS4B-NS5A-NS5B polyprotein (also referred to as NS3-NS5B) along with a suitable 5'-UTR-partial core (PC) region and 3' UTR. NS3-NS5B may contain different regions from different HCV strains. The 5'-UTR-PC region is made up of a 5'-UTR region and about 36 nucleotides of the beginning of the core. Additional regions may be present including those coding for HCV proteins or elements such as the complete core, E1, E2, p7 or NS2; and those coding for other types of proteins or elements such as a encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES), a reporter protein, or a selection protein.

The HCV 5'-UTR-PC region provides an IRES for protein translation and elements needed for replication. The HCV 5'-UTR-PC region includes naturally occurring HCV 5'UTR extending about 36 nucleotides into a HCV core encoding region, and functional derivatives thereof. The IRES and PC can be present in

different locations such as site downstream from a sequence encoding a selection protein, a reporter, protein, or an HCV polyprotein.

Functional derivatives of the 5'-UTR-PC region able to initiate translation and assist replication can be designed taking into account structural requirements for HCV translation initiation. (See, for example, Honda, *et al.*, 1996. *Virology* 222, 31-42). The effect of different modifications to a 5' UTR-PC region can be determined using techniques measuring replicon activity.

In addition to the HCV 5' UTR-PC region, other types of IRES elements can also be present in the replicon. The other types of IRES elements can be present in different locations including immediately upstream the region encoding an HCV polyprotein. Examples of non-HCV IRES elements that can be used are the EMCV IRES, poliovirus IRES, and bovine viral diarrhea virus IRES.

The HCV 3' UTR assists HCV replication. HCV 3' UTR includes naturally occurring HCV 3' UTR and functional derivatives thereof. Naturally occurring 3' UTR's include a poly U tract and an additional region of about 100 nucleotides. (Tanaka, *et al.*, 1996. *J. Virol.* 70, 3307-3312, Kolykhalov, *et al.*, 1996. *J. Virol.* 70, 3363-3371.) At least *in vivo*, the 3' UTR appears to be essential for replication. (Kolykhalov, *et al.*, 2000. *J. Virol.* 4, 2046-2051.) Examples of naturally occurring 3' UTR derivatives are described by Bartenschlager International Publication Number EP 1 043 399.

The NS3-NS5B polyprotein encoding region provides for a polyprotein that can be processed in a cell into different proteins. Suitable NS3-NS5B polyprotein sequences that may be part of a replicon include those present in different HCV strains and functional equivalents thereof resulting in the processing of NS3-NS5B to produce functional replication machinery. Proper processing can be measured by assaying, for example, HCV protein production.

An HCV replicon may contain non-HCV sequences in addition to HCV sequences. The additional sequences should not prevent replication and expression, and preferably serve a useful function. Sequences that can be used to serve a useful function include a selection sequence, a reporter sequence, transcription elements and translation elements.

A selection sequence in an HCV replicon facilitates the identification and/or isolation of a cell containing the replicon. Selection sequences providing for resistance to an agent that inhibits cell growth can be used in conjunction with some selective pressure that inhibits growth of cells not containing the selection sequence.

Examples of selection sequences include sequences encoding for antibiotic resistance, and ribozymes; and reporters compatible with cell sorting such as green fluorescence protein and beta-lactamase.

Antibiotic resistance can be used in conjunction with an antibiotic to select for cells containing replicons. Examples of selection sequences providing for antibiotic resistance are sequences encoding resistance to neomycin, hygromycin, puromycin, or zeocin.

A ribozyme serving as a selection sequence can be used in conjunction with an inhibitory nucleic acid molecule that prevents cellular growth. The ribozyme recognizes and cleaves the inhibitory nucleic acid.

A reporter sequence can be used to detect replicon replication or protein expression. Preferred reporter proteins are enzymatic proteins whose presence can be detected by measuring product produced by the protein. Examples of reporter proteins include luciferase, beta-lactamase, secretory alkaline phosphatase, beta-glucuronidase, green fluorescent protein and its derivatives. In addition, a reporter nucleic acid sequence can be used to provide a reference sequence that can be targeted by a complementary nucleic acid. Hybridization of the complementary nucleic acid to its target can be determined using standard techniques.

Replicons containing reporter sequences may or may not also contain a selection sequence. Selection sequences providing resistance to an agent that inhibits cell growth can be used in conjunction with selective pressure to select for cells maintaining the replicon. The Examples provides below illustrate that replicons containing a beta-lactamase reporter sequences are sufficiently maintained in the absence of selective pressure. In an embodiment of the present invention the replicon contains a reporter sequence (preferably, beta-lactamase), and does not contain a sequence coding for resistance to an agent that inhibits cell growth.

Additional sequences can be part of the same cistron as the HCV polyprotein or can be a separate cistron. If part of the same cistron, additional sequences coding for a protein should result in a product that is either active as a chimeric protein or is cleaved inside a cell so it is separated from HCV protein.

Selection and reporter sequences encoding a protein when present as a separate cistron should be associated with elements needed for translation. Such elements include an IRES 5' to the selection or reporter sequence.

A preferred construct is a bicistronic replicon, where one cistron encodes for a selection or reporter sequence and the second cistron encodes for HCV

proteins. More preferably, the first cistron contain a HCV 5'-UTR-PC region joined to the selection or reporter sequence; and the second cistron contains the EMCV internal ribosome entry site, NS2-NS5B or NS3-NS5B, and a 3' UTR. Examples of bicistronic constructs are illustrated by SEQ. ID. NOs. 1 and 2.

5 Preferred cells for use with a HCV replicon are Huh-7 cells and Huh-7 derived cells. "Huh-7 derived cells" are cells produced starting with Huh-7 cells and introducing one or more phenotypic and/or genotypic modifications.

VI. HCV Replicon Sequences

10 HCV sequences for use in HCV replicons include HCV sequences present in different HCV strains and functional derivatives thereof. Functional derivatives can process the HCV polyprotein and provide for HCV replication.

Replicon activity from naturally occurring sequences providing for little or no detectable replicon activity in a cell can be enhanced by producing
15 functional derivatives containing adaptive mutations. Adaptive mutations and techniques for selecting for adaptive mutations are well known in the art. (See, for example, Lohmann, *et al.*, 1999. *Science* 285, 110-113, Bartenschlager, European Patent Application 1 043 399, published October 11, 2000, Blight, *et al.*, 2000. *Science* 290:1972-1974, Lohmann, *et al.*, 2001. *Journal of Virology* 75:1437-1449,
20 and Pietschmann, *et al.*, 2001. *Journal of Virology* 75:1252-1264, 2001.)

Numerous examples of naturally occurring HCV isolates are well known in the art. HCV isolates can be classified into the following six major genotypes comprising one or more subtypes: HCV-1/(1a, 1b, 1c), HCV-2/(2a, 2b, 2c), HCV-3/(3a, 3b, 10a), HCV-4/(4a), HCV-5/(5a) and HCV-6/(6a, 6b, 7b, 8b, 9a, 11a).
25 (Simmonds, 2001. *J. Gen. Virol.*, 82, 693-712.) Examples of HCV sequences have been deposited in GenBank and described in various publications. (See, for example, Chamberlain, *et al.*, 1997. *J. Gen. Virol.*, 78, 1341-1347)

VII. Chimeric HCV Replicons and Resistance Phenotyping

30 Chimeric HCV replicons contain HCV regions from different HCV strains and can be used, for example, to measure the effect of a compound on HCV activity and to provide a template for HCV resistance phenotyping. The starting template for HCV resistance phenotyping is a functional replicon. One or more

different regions of the functional replicon can be replaced with an HCV region from a different strain, including HCV obtained from a patient infected with the virus.

The template used for HCV resistance phenotyping can contain regions from different HCV strains. Preferably, the template contains a HCV-1a 3' UTR.

5 Bases 8407-8641 of SEQ. ID. NO. 1 provide the nucleotide sequence of the HCV-1a 3' UTR.

HCV resistance phenotyping can be performed by examining the sensitivity of different HCV targets isolated from a clinical sample to experimental or approved HCV drugs using a chimeric replicon. HCV targets that can be analyzed
10 include HCV encoded enzymes such as NS2/3 protease, NS3 protease, NS3 helicase, and NS5B, as well as polynucleotide regions important for HCV replication. In different embodiments concerning HCV chimeric replicons, the replicon comprises:

- a) a HCV 3'UTR, preferably HCV-1a UTR,
- b) HCV non structural proteins from any one genotype or any
15 combination of genotypes as long as the combination supports HCV replication, different HCV genotypes include HCV-1, HCV-2, HCV-3, HCV-4, HCV-5, and HCV-6; preferably, the non-structural regions contain one region from a clinical isolate;
- c) restriction sites that are silent with respect to coding that facilitate
20 introduction of HCV sequences obtained from a clinical isolate; and
- d) a reporter gene, preferably beta-lactamase.

Resistance phenotyping can be performed by isolating an HCV target region from a clinical isolate, and transferring the region to a template replicon. An example of a procedure for constructing a chimeric HCV replicon for use in resistance
25 phenotyping is as follows:

- a) Isolation and purification: isolation and purification of HCV genomic RNAs from infected patient serum can be achieved using well known techniques. (Examples of such techniques are described in Chamberlain, *et. al.*, 1997. *J. Gen. Virol.*, 78, 1341-1347, Grahovac, *et. al.*, 2001. *J. Clin. Virol.* 20, 85-89,
30 Castelain, *et al.*, 2002. *JID* 185, 573-583, Farci, *et. al.*, 2002. *PNAS* 99, 3081-3086.)
- b) Reverse transcription of HCV RNA and PCR amplification of HCV DNA: Oligonucleotide primers specific to the highly conserved 3'-end of the 3'-non-translated regions can be used to generate cDNA copies of genomic RNA;
- c) Amplification of desired target sequences. Polymerase chain
35 reaction amplification can performed to amplify the target sequence using primers 5'

and 3' of the target sequence. The primers preferably contain restriction sites that facilitate cloning. Examples of useful restriction sites include BstZ17 I and Cla I and Bcl I; and

- 5 d) Subcloning of target sequence: Restriction enzymes are used to subclone the target sequence into a HCV replicon.

Two examples of HCV template sequences useful for resistance phenotyping are provided by SEQ. ID. NO. 1 and SEQ. ID. NO. 2. SEQ. ID. NO. 1 contains an NS2-NS5B region from HCV-1b consensus (con-1) while SEQ. ID. NO. 2 contains a NS3-NS5B region from HCV-1b consensus (con-1). SEQ. ID. NO. 2 also
10 contains useful restriction sites for subcloning NS5B. SEQ. ID. NOs. 1 and 2 both contain a beta-lactamase reporter and a HCV-1a 3' UTR.

In different embodiments of the present invention, one or more HCV regions from SEQ. ID. NOs. 1 or 2 are replaced with an HCV region from a clinical isolate. Preferably, the region from the clinical isolate is either NS2/3 protease, NS3
15 protease, NS3 helicase, NS5B or a combination thereof.

VIII. Replicon Enhanced Cells

HCV replicon enhanced cells provide a preferred system for measuring HCV replicon activity. HCV replicon enhanced cells can be isolated based on their
20 ability to support replication of a first replicon and the resulting cell population supports more efficient replication of a second replicon compared to parental cells.

The replicon enhanced cell supports chronic or persistent replication of the second HCV replicon. Enhanced cells may or may not contain the first HCV replicon used obtain the replicon enhanced cell.

25 The first HCV replicon is defined as the replicon used to select the enhanced cell population and the second replicon is defined as the replicon used to measure HCV replication. Preferably, replicon enhanced cells contain a first HCV replicon having a drug resistance gene and a second HCV replicon having a reporter. The first replicon is present in an amount (copy number) compatible with efficient
30 replication of the second HCV replicon. The combination of the two replicons in a replicon enhanced cell is particularly useful for high throughput screening.

Different HCV replicons can be constructed for use as the first replicon. A drug resistance gene can be used to isolate cells that support replication of the first replicon. Alternatively, the first replicon can encode a reporter gene that is

compatible with cell sorting which allows isolation of cells that support replication of the first replicon.

The first replicon, if present in a cell containing the second replicon, should be present in an amount compatible with efficient replication of the second HCV replicon. The enhanced phenotype of a replicon enhanced cell can be masked or inhibited if the copy number of the first replicon is too high.

If needed, the copy number of the first replicon can be reduced by treating cells with inhibitors of HCV replication or by using cell culture conditions that are not compatible with replicon replication. The latter includes maintaining the cells at high cell densities for prolonged periods of time. The second replicon can be used to monitor HCV replication in enhanced cells.

Inhibitors of HCV replicon replication include IFN- α and HCV inhibitor compounds targeting a HCV protein. Examples of HCV inhibitory compounds are described in Llinas-Brunet, *et al.*, 2000. *Bioorg Med Chem. Lett.* 10(20), 2267-2270.

The first replicon can also be made less active to reduce its copy number. A less active first replicon can be produced in different ways such as by employing regulatory elements or HCV coding sequences that provide for less activity. Regulatory elements that can be altered include ribosome binding sequences, 5' UTR, and 3' UTR sequences. The activity of a replicon can readily be tested by, for example, measuring HCV nucleic acid or protein production.

Different HCV replicons can be constructed for use as the second replicon. The second replicon in addition to containing an HCV sequence preferably contains a reporter sequence. More preferably, the second replicon contains a reporter sequence such as beta-lactamase, beta galactosidase, green fluorescence protein or luciferase.

IX. Detection Methods

Methods for detecting replicon activity include those measuring the production or activity of replicon RNA and encoded protein. Measuring includes qualitative and quantitative analysis. Preferably, replicon activity is measured using a reporter protein. A preferred reporter system is the beta-lactamase reporter system.

Beta-lactamase activity can be measured, for example, by direct visualization of cells using a fluorescence microscope. Quantitation of HCV replication can be accomplished using a CCD camera that acquires digital images and

suitable software that quantitates the number of blue and green cells present in such images. This method quantitates the number of cells in a population that harbors HCV replicons expressing beta-lactamase and this measurement is typically expressed as percentage blue cells (% Blue cells).

5 Another method for measuring beta-lactamase activity is using a fluorescence plate reader that quantitates the amount and green (~530 nm) or blue (~460 nm) fluorescence emitted by cells stimulated with light of ~405 nm. This method can be used for high throughput screening.

10 Quantitation of beta-lactamase activity can also be accomplished by FACS. This method quantitates the number of blue and green cells in a given cell population as well as the amount of blue and green fluorescence. Instruments capable of cell sorting can be used to isolate cells harboring HCV replicons expressing beta-lactamase.

15 Techniques suitable for measuring RNA production include those detecting the presence or activity of RNA. The presence of RNA can be detected using, for example, complementary hybridization probes or quantitative PCR. Techniques for measuring hybridization between complementary nucleic acid and quantitative PCR are well known in the art. (See for example, Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, Sambrook, *et al.*, *Molecular Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 20 1989, and U.S. Patent No. 5,731,148.)

 RNA enzymatic activity can be provided to the replicon by using a ribozyme sequence. Ribozyme activity can be measured using techniques detecting the ability of the ribozyme to cleave a target sequence.

25 Techniques for measuring protein production include those detecting the presence or activity of a produced protein. The presence of a particular protein can be determined by, for example, immunological techniques. Protein activity can be measured based on the activity of an HCV protein or a reporter protein sequence.

30 Techniques for measuring HCV protein activity vary depending upon the protein that is measured. Techniques for measuring the activity of different non-structural proteins such as NS2/3, NS3, and NS5B, are well known in the art. (See, for example, references provided in the Background of the Invention.)

 Assays measuring replicon activity also include those detecting virion production from a replicon that produces a virion; and those detecting a cytopathic

effect from a replicon producing proteins exerting such an effect. Cytopathic effects can be detected by assays suitable to measure cell viability.

Assays measuring replicon activity can be used to evaluate the ability of a compound to modulate HCV activities. Such assays can be carried out by providing one or more test compounds to a cell expressing an HCV replicon and measuring the effect of the compound on replicon activity. If a preparation containing more than one compound is used and found to modulate replicon activity, individual compounds or smaller groups of compounds can be tested to identify replicon active compounds.

HCV inhibitory compounds can be used to produce replicon enhanced cells and compounds having the appropriate pharmacological properties may be therapeutic compounds. The ability of a compound to serve as a therapeutic compound can be confirmed using animal models such as a chimpanzee to measure efficacy and toxicity.

X. Examples

Examples are provided below to further illustrate different features of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.

Example 1. Production Of Replicon Enhanced Cells

This example illustrates the production of replicon enhanced cells. It is not necessary to cure cells from the first replicon to obtain a cell population that is enhanced for replication of a second replicon. A preferred method to achieve this is to use a replicon (first replicon) with replication properties and replicon copy number that are compatible with enhanced replication of a second replicon.

Replicons used in the Example section have the general gene organization: HCV 5'UTR-drug resistance and/or reporter- EMCV IRES- HCV NS proteins-HCV 3'UTR. The replicon nomenclature used in the examples is as follows: the drug resistance and/or reporter gene under control of the HCV IRES is indicated first, the start of the HCV polyprotein is indicated next and the presence of adaptive mutations is indicated last. For example, a replicon harboring the S2204I adaptive mutation, expressing the neo^r gene and containing the NS3-NS5B HCV NS region is referred to as neo-NS3/si. Replicons expressing Bla instead of neo^r and containing the NS2-NS5B HCV NS region are referred to as Bla-NS2/si.

The activity of a beta-lactamase replicon (bla-NS3/si) and a replication deficient replicon (bla-NS3/si/gaa), was compared in parental Huh-7 cells, neo-NS3 cells (Huh-7 cells harboring neo-NS2 replicons), neo-NS2 (Huh-7 enhanced cells harboring neo-NS2 replicons) partially cured neo-NS2 cells harboring a reduced number of neo-NS2 replicons and cured neo-NS2 cells that do not contain replicons. Neo-NS2 cells were partially cured using interferon alpha and are referred to as JGEM cells. Neo-NS2 cells were completely cured using a potent inhibitor of HCV replication and are referred to in the examples below as JG884 cells.

Quantitation of the beta-lactamase reporter was used to measure HCV sub-genomic replication and is expressed as the percentage of beta-lactamase positive cells (% blue cells). The percentage of blue cells (%BC) at 24 hours after transfection is close to 100% in both cell lines indicating similar transfection efficiencies (Table 1). The % BC at days 3 & 6 post transfection is a measure of persistent replication.

The experiment described in Table 1 shows that the bla-NS3/si/gaa replicon did not replicate in any of the cell lines analyzed but replication of the bla-NS3/si replicon was readily detected in all cell lines both at day 3 and day 6. The activity of the bla-NS3/si replicon was significantly lower in Huh-7 and neo-NS3 cells than in the neo-NS2 cell lines.

Importantly, the replication efficiency of the bla-NS3/si replicon was comparable in neo-NS2, JGEM, and JG884 cells demonstrating that cells harboring neo-NS2 replicons do not have to be cured to support enhanced replication of a second replicon. In contrast, the activity of the bla-NS3/si replicon in the neo-NS3 cell line was similar to that observed in Huh-7 cells indicating that neo-NS3 cells were not enhanced (Table 1).

Table 1. Cells Harboring Neo-NS2 Replicons Are Enhanced For Replication Of A Replicon Expressing Beta-Lactamase			
	% Blue Cells		
Cell type	Day 1	Day 3	Day 6
Huh7	69	4	3
Neo-NS3/si	76	17	7
Neo-NS2/si	81	18	18
JGEM	81	30	28
JG 884	75	12	24

Quantitation of replicon RNA in the different cell lines indicate that neo-NS3 cells produce significantly more RNA per cell than neo-NS2 cells suggesting that the replicon copy number in neo-NS3 cells might be too high for efficient replication of a second replicon (Figure 4). These observations support the hypothesis that there is a threshold of RNA copy number above which cells are not able to efficiently support replication of a second replicon.

The enhanced phenotype of JGEM and JG884 cells is similar to neo-NS2 cells and is manifested as both increased permissiveness (*i.e.*, a greater percentage of transfected cells support replication) and increased persistence (*i.e.*, replicon maintenance). The enhanced phenotype is not dependent on the sequence of the second replicon. The observation that JGEM cells support enhanced replication of replicons harboring adaptive mutants S232I (SI), A227T (AT) and, R465G (RG) (Figure 5) is in agreement with this notion. Moreover, JGEM (Figure 5) but not Huh-7 cells (not shown) can maintain persistent replication of all three replicons for multiple cell passages without the need of drug selection pressure.

Example 2: Use Of Enhanced Cells To Generate A Cell Line To Screen Inhibitors Of HCV Replication

Examples of techniques that can be employed to create a stable cell line harboring a second replicon expressing the beta-lactamase reporter and assaying for activity is provided in this example. Replicon enhanced cells containing a first replicon can be produced as described in Example 1.

Enhanced Huh-7 cells are transfected with HCV replicon RNA encoding beta-lactamase. The resulting cell population is expanded using standard cell culture conditions (DMEM supplemented with 10% FCS, 2 mM L-glutamine, 1x non-essential amino acids, Pen/Strep) until the desired number of replicon harboring cells is obtained.

An alternative approach involves cell sorting. Cell sorting can be performed, for example, by separating cell harboring replicons three to six days after transfection from cells that do not harbor the replicon using flow cytometry assisted cell sorting. The population of cells stably maintaining the replicon expressing beta-lactamase is expanded using standard cell culture techniques until sufficient cells ($>2 \times 10^9$) to carry out the screen is obtained. Replicon harboring cells are then aliquoted, frozen and stored in liquid nitrogen.

Prior to use, frozen cells are thawed fresh in the morning of the assay or the day before and diluted in pre-warmed media to 40,000 cells/ml. Cell suspension (50 μ l) is plated into 384-well micro-titer plates. The cells are allowed to recover for at least 6 hours at 37°C in the plates before beginning an assay. 1 μ l of 25 μ M clavulanic acid in PBS and 0.25 μ l of 500 μ M test compounds in DMSO are added to the cells. The assay cell plates are then incubated for 24 hours at 37°C. To the assay plate, 10 μ l of 6x CCF4/AM substrate in loading buffer is added with a Multidrop (Labsystems), and the plate incubated for 90 minutes at ambient temperature. The plate is then read from the bottom on a Teacn Spectrafluor Plus (340nm excitation, 460nm and 530nm emissions).

Example 3: Use Of Clavulanic Acid To Sensitize An HCV Replicon Beta-Lactamase Assay To Inhibitors Of HCV Replication

In the example described below, clavulanic acid is present throughout the assay at a concentration that slightly reduces beta-lactamase activity instead of using it at high concentration that would complete inhibit beta-lactamase activity. Because clavulanic acid is an irreversible inhibitor, it is a more potent inhibitor of beta-lactamase at low enzyme concentrations than at high enzyme concentrations and therefore its inhibitory activity has a more pronounced effect in the background signal than in the foreground signal which in turn explains the enhancement of the signal-to-background ratio from the beta-lactamase reporter.

Table 2 provides results obtained using different concentrations of clavulanic acid and an HCV NS5B inhibitor.

Table 2. Improved Potency Of An NS5B Inhibitor In The Presence Of Increasing Concentrations Of Clavulanic Acid			
[CA] μ M	S/B	Δ	IC ₅₀ μ M
0.00	3.5	1.23	1.3
0.13	5.7	1.22	0.94
0.25	6.0	1.17	0.84
0.50	6.3	0.97	0.54
1.00	5.4	0.81	0.42

The experiment in Figure 6 shows that in the absence of clavulanic acid, the half-life of beta-lactamase activity in the replicon assay is approximately 14.9 hours but in the presence of 0.5 μ M of clavulanic acid the half life of beta-lactamase activity is 4.7 hours. The lower half life of beta-lactamase in the presence of clavulanic acid improves the signal to noise ratio of a 24 hour assay.

Example 4. Use Of A Beta-Lactamase Reporter System To Enrich Cell Populations Harboring HCV Replicons

JGEM cells were lipotransfected with bla-NS2/si (BK 3'-UTR) replicon RNA using DMRIE-C (transfection reagent, Invitrogen Life Technologies) and expanded under standard growth conditions. Cells were stained with CCF4/AM for 90 minutes, dissociated from the flask with 0.25% trypsin/1 mM EDTA, and then suspended in sort buffer (PBS with 0.1% bovine serum albumin and pen/strep).

Cells were then sorted using Becton-Dickenson FACS Vantage SE cell sorter equipped with Coherent Innova 70C-4 (488 nm) and Coherent 302C Krypton (407 nm) lasers. Optical filters used on the cell sorter were 530/30 and 450/30 bandpass filters separated by a 490 dichroic mirror. Cells were sorted at a rate of 10,000 cells/s.

Cells staining positive for beta-lactamase expression were collected in complete medium containing 20% fetal calf serum. Medium was replaced the following day with complete medium containing 10% FCS. Cells were assayed for % blue cells by digital image processing at the indicated intervals. Cells maintained replicon for at least two weeks as indicated by the high percentage of cells that stain positive for the beta-lactamase reporter (Table 3).

Table 3. Enrichment Of A Cell Population Harboring An HCV Replicon Expressing Beta-Lactamase	
Day Post Sort	% Blue Cells
Pre-sort	10
Day 1	83
Day 4	89
Day 8	82
Day 14	73
Day 15	75

Example 5. Use Of A Beta-Lactamase Reporter System To Identify Functional HCV Sequences

5 HCV BK is a genotype 1b clone that is infectious in chimpanzees. BK replicons with and without the NS5A S2204I adaptive mutation were generated and tested for their ability to replicate using the beta-lactamase reporter. The replicon without the S2204I adaptive mutation failed to replicate in JGEM cells, while the replicon with the mutation replicated with modest efficiency.

10 A series of BK and con1 chimeras were generated to identify the region(s) that accounts for the different replicative activities of the two replicons. JGEM cells were lipotransfected with chimeric replicon RNAs and then cultured for 4 days under standard growth conditions. As shown in Table 4, replacement of the BK NS3 sequence with that from the con1 replicon resulted in a dramatic improvement in replication. In other BK/con1 chimeras, most of the differences in replication
15 efficiency tracked with the NS3 sequence used while other parts of the genome had more modest or no effects on the observed differences in replication efficiency.

Table 4. Identification Of Functional HCV Sequence Using Beta-Lactamase Reporter System	
Replicon	% Blue Cells
Bla-BK NS3	0.05
Bla-Bk NS3/SI	2.05
Bla-BK NS3 with con 1 NS3	0.13
Bla-BK NS3/SI with con 1 NS3	49.9
Bla-NS3/SI	44.2
Bla-NS3/SI with BK NS3	0.71

20 **Example 6. Production Of Functional Chimeric Replicons For Resistance Phenotyping**

This example illustrates resistance phenotyping with NS5B. BstZ17 I and Cla I restrictions sites were introduced at the 5' - and 3' - ends of the NS5B coding region, respectively. The nucleotide substitutions made to introduce these restriction sites do not affect amino acid coding. The BstZ17 I and Cla I sites are unique in the
25 resulting construct and facilitate rapid subcloning of NS5B sequences from clinical

isolates for phenotypic analysis. As shown in Table 5, the nucleotide changes required to introduce the restriction sites do not affect replication.

Viral RNA was purified from 140 μ l of infected patient serum (10^3 - 10^6 copies/ml) using the Qiagen viral RNA purification kit according to the manufacturer's directions followed by phenol:chloroform extraction and ethanol precipitation. cDNAs were generated by reverse transcription of 1/20 to 1/5 of the sample using a poly(A) oligonucleotide primer and Superscript II reverse transcriptase (Gibco-BRL) according to the manufacturer's guidelines.

NS5B coding regions were amplified by nested PCR using Expand High Fidelity polymerase (Roche). The initial amplification reaction was carried out using a primer that anneals immediately upstream of the NS5B coding region and the poly(A) primer used for reverse transcription. The second amplification used primers (sequences) that anneal at the 5'- and 3'- ends of the NS5B coding region internal to the primers used in the initial PCR reaction.

Amplification products were cloned directly into pGEM T-vector (Promega). The NS5B coding regions were subsequently amplified using a sense primer that included Bcl I restriction site and an antisense primer designed to introduce a Cla I site at the 3'-end. Amplification products were subcloned into the corresponding sites of SEQ. ID. NO. 2 to generate chimeric viruses containing the NS5B sequences derived from the clinical samples.

Replication of the chimeric replicons was characterized by using the beta-lactamase reporter assay as described above. As shown in Table 5, functional replicons with NS5B sequences from another genotype 1b isolate and from a genotype 1a isolate were functional in the context of the resistance phenotyping replicon.

Table 5. Functional Chimeric Replicons For Resistance Phenotyping	
Replicon	% Blue Cells
Bla-NS3/si con1 NS5B (Cla I)	34.0
Bla-NS3/si (BstZ17 I) con1 NS5B (Cla I)	33.2
Bla-NS3/si (BstZ17 I) HC(1b) NS5B (Cla I)	30.0
Bla-NS3/si (BstZ17 I) RB(1a) NS5B (Cla I)	6.3
Bla-NS3/si (GAA)	0.3

Example 7: Importance of 3'-UTR

NS2 replicon constructs that expressed a beta-lactamase reporter and that contained either the con1 or HCV 1a 3'-UTR were generated using techniques well known in the art. Replication of the resulting replicons was analyzed by digital image processing or using a fluorescent plate reader. As shown in Table 6, the replicon containing the HCV 1a 3'-UTR replicates more efficiently than the corresponding replicon containing the con1 3'-UTR.

Table 6. Enhancement Of Replication With HCV 1a 3'-UTR		
Replicon	% Blue Cells	Em460/Em530 x100
Bla-NS2/BK NS5B with con1 3'-UTR	11.3	14.0
Bla-NS2/BK NS5B with 1a 3'UTR	32.5	41.2
Bla-NS2(con1)/si with con1 3'UTR	23.9	22.3
Bla-NS2(con1)/si with 1a 3' UTR	42.6	56.3
Bla-NS2/si/GAA	0.2	5.3
Mock	0.0	0.0

10

Other embodiments are within the following claims. While several embodiments have been shown and described, various modifications may be made without departing from the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

1. A method of measuring the ability of a compound to alter HCV activity using a beta-lactamase reporter system comprising the steps of:
 - 5 a) combining together said compound, a screening cell and a beta-lactamase substrate under conditions supporting beta-lactamase activity, wherein said screening cell harbors a first HCV replicon comprising a selection sequence and a second HCV replicon comprising a nucleotide sequence encoding a beta-lactamase; and
 - 10 b) measuring the ability of said compound to alter beta-lactamase production.
2. The method of claim 1, wherein said cell is a Huh-7 cell or is derived from a Huh-7 cell.
- 15 3. The method of claim 2, further comprising the use of clavulanic acid in an amount effective to enhance signal-to-background ratio.
4. The method of claim 2, wherein said HCV replicon is a
20 chimeric replicon comprising one or more HCV regions from two or more HCV strains, wherein at least one of the regions is a HCV-1a 3' UTR.
5. The method of claim 4, wherein at least one of said regions is a non-structural region from a clinical isolate.
- 25 6. The method of claim 4, wherein said second HCV replicon consists of either a modified version of SEQ ID NO: 1 or a modified version of SEQ ID NO: 2, wherein said modified version of SEQ ID NO: 1 contains SEQ ID NO: 1 modified by replacing the NS5B region with a NS5B region from a clinical isolate and
30 said modified version of SEQ ID NO: 2 contains SEQ ID NO: 2 modified by replacing the NS5B region with a NS5B region from a clinical isolate.
7. A HCV replicon enhanced cell comprising a first HCV replicon and a second HCV replicon, wherein said first HCV replicon comprises a selection

sequence, said cell supports chronic or persistent replication of said second HCV replicon and said second HCV replicon is different from said first HCV replicon.

8. The HCV replicon enhanced cell of claim 7, wherein said cell
5 is a Huh-7 cell or is derived from a Huh-7 cell.

9. The HCV replicon enhanced cell of claim 8, wherein said second HCV replicon comprises a beta-lactamase reporter.

10. The HCV replicon enhanced cell of claim 9, wherein said second HCV replicon is a chimeric replicon comprising one or more HCV regions from two or more HCV strains, wherein at least one of the regions is a HCV-1a 3' UTR.

11. A method of producing an HCV replicon enhanced cell comprising a first and a second replicon comprising the steps of:

- a) introducing into a cell said first HCV replicon, wherein said first replicon comprises a selection sequence,
- b) obtaining a replicon enhanced cell, wherein said replicon enhanced
20 cell supports chronic or persistent replication of said first replicon; and
- c) introducing into said replicon enhanced cell said second replicon, wherein said second replicon comprising a reporter,
provided that said first replicon is present in an amount compatible with replication of said second replicon.

12. The method of claim 11, wherein said cell is a Huh-7 cell or is derived from a Huh-7 cell.

13. The method of claim 12, further comprising the step of partially
30 curing said first replicon from said cell.

14. The method of claim 13, wherein said reporter is beta-lactamase.

15. The method of claim 13, wherein said first HCV replicon is a chimeric replicon comprising one or more HCV regions from two or more HCV strains, wherein at least one of the regions is a HCV-1a 3' UTR.

5 16. The method of claim 15, wherein at least one of said regions is a non-structural region from a clinical isolate.

10 17. The method of claim 15, wherein said second HCV replicon consists of either a modified version of SEQ ID NO: 1 or a modified version of SEQ ID NO: 2, wherein said modified version of SEQ ID NO: 1 contains SEQ ID NO: 1 modified by replacing the NS5B region with a NS5B region from a clinical isolate and said modified version of SEQ ID NO: 2 contains SEQ ID NO: 2 modified by replacing the NS5B region with a NS5B region from a clinical isolate.

15 18. A HCV replicon comprising a beta-lactamase reporter, wherein said replicon does not contain a sequence coding for resistance to an agent that inhibits cell growth.

20 19. A chimeric HCV replicon comprising one or more HCV regions from two or more HCV strains, wherein at least one of the regions is a HCV-1a 3' UTR.

25 20. The chimeric HCV replicon of claim 19, wherein at least one of said regions is a non-structural region from a clinical isolate.

30 21. The chimeric HCV replicon of claim 19, wherein said HCV replicon consists of either a modified version of SEQ ID NO: 1 or a modified version of SEQ ID NO: 2, wherein said modified version of SEQ ID NO: 1 contains SEQ ID NO: 1 modified by replacing the NS5B region with a NS5B region from a clinical isolate and said modified version of SEQ ID NO: 2 contains SEQ ID NO: 2 modified by replacing the NS5B region with a NS5B region from a clinical isolate.

35 22. The chimeric HCV replicon of claim 21, wherein said replicon consists of either SEQ ID NO: 1 or SEQ ID NO 2.

23. The chimeric HCV replicon of claim 20, wherein said replicon comprises restriction sites not present in naturally occurring HCV that are located about 3' and about 5' from an HCV target region, wherein said restriction sites do not affect replicon activity.

5

24. The chimeric HCV replicon of claim 23, wherein said restriction sites are silent with respect to amino acid coding.

25. The chimeric HCV replicon of any one of claims 19, 20, 23, or
10 24, wherein said chimeric replicon comprises a beta-lactamase reporter.

26. The chimeric HCV replicon of claim 25, wherein said replicon does not contain a sequence coding for resistance to an agent that inhibits cell growth.

1/12

1 gccagccccc gauugggggc gacacuccac cauagauac uccccuguga ggaacuacug
61 ucuucacgca gaaagcgucu agccauggcg uuaguaugag ugucgugcag ccuccaggac
121 cccccucucc gggagagcca uaguggucug cggaaccggu gaguacaccg gaauugccag
181 gacgaccggg uccuuucuuu gaucaacccg cucaauggccu ggagauuugg gcgugccccc
241 gcgagacugc uagccgagua guguuugguc gcgaaaggcc uugugguacu gccugauagg
301 gugcuugcga gugccccggg aggucucgua gaccgugcac caugagcacg aauccuaaac
361 cucaaagaaa aaccaaaggg cgcgccaugc acccagaaac gcuggugaaa guaaaagaug
421 cugaagauca guugggugca cgaguggguu acaucgaacu ggaucaaac agcgguaga
481 uccuugagag uuuucgcccc gaagaacguu uuccaaugau gagcacuuuu aaaguucugc
541 uauguggcgc gguauuaucc cguauugacg ccgggcaaga gcaacucggu cgccgcauac
601 acuaauucua gaaugacuug guugaguacu caccagucac agaaaagcau cuuacggaug
661 gcaugacagu aagagaauua ugcagugcug ccuaaaccu gagugauaac acugcggccca
721 acuuacuucu gacaacgauc ggaggaccga aggagcuaac cgcuuuuuug cacaacaugg
781 gggaucaugu aacucgccuu gaucguuggg aaccggagcu gaugaagcc auaccaaacg
841 acgagcguga caccacgaug ccuguagcaa uggcaacaac guugcgcaa cuauuaacug
901 gcgaacuacu uacucuagcu ucccggcaac aauuaauaga cuggauggag gcggauaaag
961 uugcaggacc acuucugcgc ucggcccuuc cggcuggcug guuuauugcu gauaaaucug
1021 gagccgguga gcgugggucu cgcgguauc uugcagcacu ggggccagau gguaagcccu
1081 cccguaucgu aguuaucua acgacgggga gucaggcaac uauggaugaa cgaaauagac
1141 agaucgcuga gauaggugcc ucacugauua agcauuggua aguuuaaaca gaccacaacg
1201 guuuccucuc agcgggauc auuccgcccc ucucccucc ccccccuua cguuacuggc
1261 cgaagccgcu uggaauaagg ccggugugcg uuugucuaua uguuauuuuc caccuauug
1321 ccgucuuuug gcaaugugag ggcccggaaa ccuggcccug ucuucugac gagcauuccu
1381 aggggucuuu cccucucgc caaaggaaug caaggucugu ugaaugucgu gaaggaagca
1441 guuccucugg aagcuucuu aagacaaaca acgucuguag cgaccuuug caggcagcgg
1501 aacccccac cuggcgacag gugccucugc ggccaaaagc cacguguaua agauacaccu
1561 gcaaaggcgg cacaaccca gugccacguu gugaguugga uaguugugga aagagucaaa
1621 uggcucuccu caagcguauu caacaagggg cugaaggau cccagaaggu accccauugu
1681 augggauucg aucugggggc ucggugcaca ugcuuuacau guguuuaguc gagguaaaaa
1741 aacgucuagg ccccccgaac cacggggacg ugguuuuccu uugaaaaaca cgauauuacc
1801 auggaccggg agauggcagc aucgugcgga ggcgcgguu ucguaggucu gauacucuug
1861 accuugucac cgcacuauaa gcuguuccuc gcuaggcuca uauggguguu acaauuuuu
1921 aucaccaggg ccgaggcaca cuugcaagug uggaucuccc cccucaacgu ucggggggggc
1981 cgcgaugccg ucauccuccu cacgugcgcg auccaccag agcuauucuu uaccauacc
2041 aaaaucuugc ucgccauacu cgguccacuc auggugcucc aggcugguau aaccaaagug
2101 ccguacuucg ugcgcgcaca cgggcucau cgugcaugca ugcuggugcg gaagguugcu
2161 gggggucauu auguccaaau ggcucucaug aaguuggccg cacugacagg uacguacguu
2221 uaugaccauc ucacccacu gcgggacugg gccacgcgg gccuacgaga ccuugcggu
2281 gcaguugagc ccgucgucu cucugauaug gagaccaagg uauaccucg gggggcagac
2341 accgcggcgu guggggacau caucuugggc cugcccguu cgcggcag ggggagggag
2401 auacaucugg gaccggcaga cagccuugaa gggcaggggu ggcgacuccu cgcgccuauu
2461 acggccuacu cccaacagac gcgaggccua cuuggcugca ucaucacuag ccucacaggc

FIG. 1A

2/12

2521 cgggacagga accaggucga gggggagguc caaguggucu ccaccgcaac acaaucuuuc
2581 cuggcgaccu gcguaaugg cguguguugg acugucuauc auggugccgg cucaaagacc
2641 cuugccggcc caaagggccc aaucacccaa auguacacca auguggacca ggaccucguc
2701 ggcuggcaag cgcccccccg ggcgcguucc uugacaccac gcaccugcgg cagcucggac
2761 cuuuacuugg ucacgaggca ugccgauguc auuccggugc gccggcgggg cgacagcagg
2821 gggagccuac ucucccccag gcccgucucc uacuugaagg gcucuucggg cgguccacug
2881 cucugccccc cggggcacgc ugugggcauc uuucgggcug ccgugugcac ccgagggguu
2941 gcgaaggcgg uggacuuguu acccgucgag ucuauggaaa ccacuaugcg guccccgguc
3001 uucacggaca acucgucccc uccggccgua ccgcagacau uccagguggc ccaucuacac
3061 gcccucacug guagcggcaa gagcacuaag gugccggcug cguaugcagc ccaagggauu
3121 aaggugcuug uccugaaccc guccgucgcc gccaccuag guuucggggc guauaugucu
3181 aaggcacaug guaucgaccc uaacaucaga accgggguaa ggaccaucac caggggugcc
3241 ccaucacgu acuccaccua uggcaaguuu cuugccgacg gugguugcuc ugggggcgcc
3301 uaugacauca uauauguga ugagugccac ucaacugacu cgaccacuau ccugggcauc
3361 ggcacagucc uggaccaagc ggagacggcu ggagcgcgac ucgucgugcu cgccaccgcu
3421 acgccuccgg gaucggucac cgugccacau ccaaacaucg aggagguggc ucuguccagc
3481 acuggagaaa uccccuuua uggcaaagcc auccccaucg agaccaucaa gggggggagg
3541 caccucauuu ucugccauuc caagaagaaa ugugaugagc ucgccgcgaa gcuguccggc
3601 cucggacuca augcuguagc auauuaccgg ggccuugaug uauccgucau accaacuagc
3661 ggagacguca uugucguagc aacggacgcu cuaaugacgg gcuuuaccgg cgauuucgac
3721 ucagugaucg acugcaauac augugucacc cagacagucg acuucagccu ggacccgacc
3781 uucaccauug agacgacgac cgugccacaa gacgcggugu cacgcucgca gcggcgaggc
3841 aggacuggua ggggcaggau gggcauuuac agguuuguga cuccaggaga acggcccucg
3901 ggcauguucg auuccucggu ucugugcgag ugcuaugacg cgggcugugc uugguacgag
3961 cucacgccc cggagaccuc aguuauguug cgggcuuacc uaaacacacc agggguugccc
4021 gucugccagg accaucugga guucugggag agcgucuuua caggccucac ccacauagac
4081 gcccuuuucu ugucccagac uaagcaggca ggagacaacu ucccuuaccu gguagcauac
4141 caggcuacgg ugugcgccag ggcucaggcu ccaccuccau cgugggacca aauguggaag
4201 ugucucauac ggcuaaagcc uacgcugcac gggccaacgc ccugcugua uaggcuggga
4261 gccguucaa acgagguuac uaccacacac ccuauacca aaauacauca ggcaugcaug
4321 ucggcugacc uggaggucgu cacgagcacc ugggugcugg uaggcgaggu ccuagcagcu
4381 cuggcccgcu auugccugac aacaggcagc guggucauug ugggcaggau caucuugucc
4441 ggaaagccgg ccaucauucc cgacaggga guccuuuacc gggaguucga ugagauggaa
4501 gagugcgccu cacaccuccc uuacaucgaa cagggaauagc agcucgccga acaauucaa
4561 cagaaggcaa ucggguugcu gcaaacagcc accaagcaag cggaggcugc ugcucccgug
4621 guggaaucca aguggcggac ccucgaagc uucugggcga agcauauug gaauuacau
4681 agcgggauac aaauuuuagc agguugucc acucugccug gcaaccccgc gauagcauca
4741 cugauggcau ucacagccuc uaucaccagc ccgcucacca ccaacauac ccuccuguuu
4801 aacauccugg ggggaugggu ggcgccccaa cuugcuccuc ccagcgcugc uucugcuuuc
4861 guaggcgccg gcaucgugc agcggcuguu ggcagcauag gccuugggaa ggugcuugug
4921 gauauuuugg cagguuaugg agcaggggug gcaggcgcgc ucguggccuu uaaggucaug
4981 agcggcgaga ugcccuccac cgaggaccug guuaaccuac uccugcuau ccucucccu

FIG. 1B

3/12

5041 ggcgcccua g ugcuggggu cgugugcgca gcgauacugc gucggcacgu gggcccaggg
5101 gagggggcug ugcaguggau gaaccggcug auagcguucg cuucgcgggg uaaccacguc
5161 uccccacgc acuaugugcc ugagagcgac gcugcagcac gugucacuca gauccucucu
5221 agucuuacca ucacucagcu gcugaagagg cuucaccagu ggaucaacga ggacugcucc
5281 acgccaugcu cgggcucgug gcuaagagau guuugggauu ggauaugcac gguguugacu
5341 gauuuaaga ccuggcucca guccaagcuc cugccgcgau ugccgggagu ccccuucuc
5401 ucaugucaac guggguacaa gggagucugg cggggcgacg gcaucaugca aaccaccugc
5461 ccauguggag cacagauca cggacaugug aaaaacgguu ccaugaggau cgugggggccu
5521 aggaccugua guaacacgug gcauggaaca uccccauua acgcguaacac cacgggcccc
5581 ugcacgccc ccccggcgcc aaauuauucu agggcgcgug ggcggguggc ugcugaggag
5641 uacguggagg uuacggggg gggggauuuc cacuacguga cgggcaugac cacugacaac
5701 guaaagugcc cgugucaggu uccggcccc gaauucuaa cagaagugga uggggugcgg
5761 uugcacaggu acgcuccagc gugcaaacc cuccuacggg aggaggucac auuccuguc
5821 gggcucauc auuaccuggu ugggucacag cuccaugcg agcccgaacc ggacguagca
5881 gugcucacuu ccaugcucac cgacccucc cacauuacgg cggagacggc uaagcguagg
5941 cuggccaggg gaucuccccc cuccuuggcc agcucaucag cuauccagcu gucugcgccu
6001 uccuugaagg caacaugcac uacccgucac gacucccg agcugaccu caucgaggcc
6061 aaccuccugu ggcggcagga gaugggcggg acauacacc gcguggaguc agaaaaaag
6121 guaguaauuu uggacucuuu cgagccgcuc caagcgagg aggaugagag ggaaguauc
6181 guuccggcg agauccugcg gagguccagg aaauuccuc gagcgaugcc cauaugggca
6241 cgcccggaau acaaccucc acuguuagag uccuggaagg acccggauc cguccucca
6301 gugguacacg gguguccau gccgcugcc aaggccccuc cgauaccacc uccacggagg
6361 aagaggacgg uuguccuguc agaauuacc gugucuucg ccuuggcgga gcucgccaca
6421 aagaccuucg gcagcuccga aucgucggc gucgacagcg gcacggcaac ggccucuccu
6481 gaccagcccu ccgacgacgg cgacgcggga uccgacguug agucguacuc cuccaugccc
6541 ccccuagagg gggagccggg ggaucggau cucagcgac ggucuugguc uaccguaagc
6601 gaggaggcua gugaggacgu cgucugcugc ucgauguccu acacauggac aggcgcccug
6661 aucacgccau gcgcugcgga ggaaaccaag cugcccuaa augcacugag caacucuuug
6721 cuccgucacc acaacuuggu cuaugcuaca acaucgcga gcgcaagccu gcggcagaag
6781 aaggucaccu uugacagacu gcagguccug gacgaccacu accgggacgu gcuaaggag
6841 augaaggcga aggcguccac aguuaaggcu aaacuucua ccguggagga agccuguaag
6901 cugacgcccc cacauucggc cagaucuaa uuuggcuau gggcaaagga cguccggaac
6961 cuauccagca aggccguua ccacaucgcg uccgugugga aggacuugcu ggaagacacu
7021 gagacaccaa uugacaccac caucauggca aaaaugagg uuuucugcg ccaaccagag
7081 aaggggggcc gcaagccagc ucgccuuauc guauuccag auuugggggu ucgugugugc
7141 gagaaaugg cccuuuacga uguggucucc acccuccuc aggccgugau gggcucuua
7201 uacggauucc aaucucucc uggacagcgg gucgaguucc uggugaauug cuggaaagcg
7261 aagaaugcc cuaugggcuu cgcauauag acccgcuuu uugacucaac ggucacugag
7321 aaugacauc gugugagga gucaauuac caauguugug acuuaggccc cgaagccaga
7381 caggccaaua ggucgcucac agagcgguu uacaucgggg gccccugac uaaucuaa
7441 gggcagaacu gcggcuauug cggugccgc gcgagcgug uacugacgac cagcugcggu
7501 aaaucccuca cauguuacuu gaaggccgc gcggccugc gagcugcgaa gcuccaggac

FIG. 1C

4/12

7561 ugcacgaugc ucguaugcgg agacgaccuu gucguuauuc gugaaagcgc ggggacccaa
7621 gaggacgagg cgagccuacg ggccuucacg gaggcuauga cuagauacuc ugccccccu
7681 ggggacccgc ccaaaccaga auacgacuug gaguugauaa caucaugcuc cuccaaugug
7741 ucagucgcgc acgaugcauc uggcaaaagg guguacuauc ucacccguga cccaccacc
7801 ccccuugcgc gggcugcgug ggagacagcu agacacacuc cagucaauuc cuggcuaggc
7861 aacaucauca uguaugcgcc caccuugugg gcaaggaua uccugaugac ucauuucuc
7921 uccaucucuc uagcucagga acaacuugaa aaagcccuag auugucagau cuacggggcc
7981 uguuacucca uugagccacu ugaccuaccu cagaucauuc aacgacucca uggccuagc
8041 gcuuuuucac uccauaguua cucuccaggu gagaucaaua ggguggcuuc augccucagg
8101 aaacuugggg uaccgcccuc gcgagucugg agacaucggg ccagaagugu ccgcgcuaagg
8161 cuacuguccc aggggggggag ggcugccacu uguggcaagu accucucaa cugggcagua
8221 aggaccaagc ucaaacucac uccaaucgg gcugcguccc aguuggauuu auccagcugg
8281 uucguugcug guuacagcgg gggagacaua uaucacagcc ugucucgugc ccgacccgc
8341 ugguucaugu ggugccuacu ccuacuuuc guagggguag gcaucuauc acuccccaau
8401 cgaugaaggu ugggguaaac acuccggccu cuuaggccau uuccucucu uuuuuuguu
8461 uuugggguu uuuguuuuu uuucuuuuu uuuuuuuuu uuucuuuuu ccuucuccu
8521 uuucucuuu uuucucuuu aaugguggcu ccaucuuagc ccuagucacg gcuagcugug
8581 aaagguccgu gagccgcaug acugcagaga gugcugauac ugccucucu gcagauaug
8641 ugguucggca uggaucucc accucccgc gguccgaccu gggcauccga aggaggacgu
8701 cguccacug gauggcuaag ggagagcucu ag

FIG. 1D

5/12

1 gccagccccc gattgggggc gacactccac catagatcac tcccctgtga ggaactactg
61 tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgtcgtgcag cctccaggac
121 cccccctccc gggagagcca tagtgggtctg cggaaccggt gagtacaccg gaattgccag
181 gacgaccggg tcctttcttg gatcaacccg ctcaatgcct ggagatttgg gcgtgcccc
241 gcgagactgc tagccgagta gtgttgggtc gcgaaaggcc ttgtggtact gcctgatagg
301 gtgcttgcca gtgccccggg aggtctcgtg gaccgtgcac catgagcacg aatcctaaac
361 ctcaaagaaa aaccaaaggg cgcgccatgc acccagaaac gctggtgaaa gtaaaagatg
421 ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga
481 tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc
541 tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggg cgccgcatac
601 actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg
661 gcatgacagt aagagaatta tgcagtgtcg ccataaccat gagtataaac actgcggcc
721 acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg
781 gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg
841 acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg
901 gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag
961 ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg
1021 gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct
1081 cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac
1141 agatcgctga gatagggtgcc tctactgatta agcattggta agtttaaca gaccacaacg
1201 gtttccctct agcgggatca attccgcccc tctccctccc cccccctaa cgttactggc
1261 cgaagccgct tggaataagg ccggtgtgcg tttgtctata tgttattttc caccatattg
1321 ccgtcttttg gcaatgtgag ggcccggaaa cctggccctg tcttcttgac gagcattcct
1381 aggggtcttt cccctctcgc caaaggaatg caaggctctgt tgaatgtcgt gaaggaagca
1441 gtctctctgg aagcttcttg aagacaaaca acgtctgtag cgacccttg caggcagcgg
1501 aacccccac ctggcgacag gtgcctctgc ggccaaaagc cacgtgtata agatacacct
1561 gcaaaggcgg cacaacccca gtgccacgtt gtgagttgga tagttgtgga aagagtcaaa
1621 tggctctcct caagcgtatt caacaagggg ctgaaggatg ccagaagggt accccattgt
1681 atgggatctg atctggggcc tcggtgcaca tgctttacat gtgttttagtc gaggttaaaa
1741 aacgtctagg cccccgaac cacggggacg tggttttcct ttgaaaaaca cgataatacc
1801 atgggcctta ttacggccta ctcccaacag acgcgaggcc tacttggctg catcatcact
1861 agcctcacag gccgggacag gaaccaggtc gagggggagg tccaagtggg ctccaccgca
1921 acacaatctt tcctggcgac ctgcgtcaat ggcgtgtgtt ggactgtcta tcatggtgcc
1981 ggctcaaaga cccttgccgg cccaaagggc ccaatcacc aaatgtacac caatgtggac
2041 caggacctcg tcggctggca agcgcceccc ggggcgcgtt ccttgacacc atgcacctgc
2101 ggcagctcgg acctttactt ggtcacgagg catgccgatg tcattccggg gcgccggcgg
2161 ggcgacagca gggggagcct actctcccc aggccgtct cctacttgaa gggctcttcg
2221 ggcggtccac tgctctgccc ctccggggcac gctgtgggca tctttcgggc tgccgtgtgc
2281 acccgagggg ttgcgaaggc ggtggacttt gtaccgctcg agtctatgga aaccactatg
2341 cggccccggg tcttcacgga caactcgtcc cctccggccg taccgcagac attccagggtg
2401 gcccatctac acgcccctac tggtagcggc aagagcacta aggtgccggc tgcgtatgca
2461 gcccaagggt ataaggtgct tgtcctgaac ccgtccgtcg ccgccaccct aggtttcggg

FIG. 2A

6/12

2521 gcgtatatgt ctaaggcaca tggatatgac cctaacaatca gaaccgggggt aaggaccatc
2581 accacggggtg ccccatcac gtactccacc tatggcaagt ttcttgccga cggtggttgc
2641 tctgggggcg cctatgacat cataatatgt gatgagtgcc actcaactga ctcgaccact
2701 atcctgggca tcggcacagt cctggaccaa gcggagacgg ctggagcgcg actcgctgtg
2761 ctgccaccg ctacgcctcc gggatcggtc accgtgccac atccaaacat cgaggagggtg
2821 gctctgtcca gcactggaga aatccccctt tatggcaaag ccatccccat cgagaccatc
2881 aaggggggga ggcacctcat tttctgccat tccaagaaga aatgtgatga gctcgccgcg
2941 aagctgtccg gcctcggact caatgctgta gcatattacc ggggccttga tgtatccgtc
3001 ataccaacta gcggagacgt cattgtcgta gcaacggacg ctctaataac gggctttacc
3061 ggcgatttcg actcagtgat cgactgcaat acatgtgtca cccagacagt cgacttcagc
3121 ctggaccgga ccttcaccat tgagacgacg accgtgccac aagacgcggg gtcacgctcg
3181 cagcggcgag gcaggactgg taggggcagg atgggcattt acaggtttgt gactccagga
3241 gaacggccct cgggcatgtt cgattcctcg gttctgtgcg agtgctatga cgcgggctgt
3301 gcttggtagc agctcacgcc cgccgagacc tcagttaggt tgccggctta cctaaacaca
3361 ccagggttgc cgtctgcca ggaccatctg gaggttctgg agagcgtctt tacaggcctc
3421 acccatag acgcccattt cttgtcccag actaagcagg caggagacaa cttcccctac
3481 ctggtagcat accaggctac ggtgtgcgcc agggctcagg ctccacctcc atcgtgggac
3541 caaatgtgga agtgctcat acggctaaag cctacgctgc acgggccaac gccctgctg
3601 tataggctgg gagccgttca aaacgaggtt actaccacac acccataaac caataacatc
3661 atggcatgca tgtcggctga cctggaggtc gtcacgagca cctgggtgct ggtaggcgga
3721 gtcctagcag ctctggccgc gtattgcctg acaacaggca gcgtgggtcat tgtgggcagg
3781 atcatcttgt ccggaaagcc ggccatcatt cccgacaggg aagtccttta ccgggagttc
3841 gatgagatgg aagagtgcgc ctcacacctc cttacatcg aacagggaat gcagctcgcc
3901 gaacaattca aacagaaggc aatcgggttg ctgcaaacag ccaccaagca agcggaggct
3961 gctgctcccg tgggtggaatc caagtggcgg accctcgaag ccttctgggc gaagcatatg
4021 tggaatttca tcagcgggat acaatattha gcaggcttgt ccactctgcc tggcaacccc
4081 gcgatagcat cactgatggc attcacagcc tctatcacca gcccgctcac caccacat
4141 accctcctgt ttaacatcct ggggggatgg gtggccgccc aacttgctcc tccagcgct
4201 gcttctgctt tcgtaggcgc cggcatcgct ggagcggctg ttggcagcat aggccttggg
4261 aaggtgcttg tggatathtt ggcaggttat ggagcagggg tggcaggcgc gctcgtggcc
4321 tttaaggtea tgagcggcga gatgcctcc accgaggacc tggttaacct actccctgct
4381 atcctctccc ctggcgccct agtcgtcggg gtcgtgtgcg cagcgatact gcgtcggcac
4441 gtggggccag gggagggggc tgtgcagtgg atgaaccggc tgatagcgtt cgcttcgagg
4501 ggtaaccacg tctccccac gcactatgtg cctgagagcg acgctgcagc acgtgtcact
4561 cagatcctct ctagtcttac catcactcag ctgctgaaga ggcttcacca gtggatcaac
4621 gaggactgct ccacgccatg ctccggctcg tggctaagag atgtttggga ttggatatgc
4681 acggtgttga ctgatttcaa gacctggctc cagtccaagc tcctgccgag attgccggga
4741 gtccccctct tctcatgtca acgtgggtac aagggagtct ggccggggcg cggcatcatg
4801 caaaccacct gcccatgtgg agcacagatc accggacatg tgaaaaacgg ttccatgagg
4861 atcgtggggc ctaggacctg tagtaaacag tggcatggaa cattccccat taacgcgtac
4921 accacggggc cctgcacgcc ctccccggcg ccaaattatt ctaggcgct gtggcgggtg
4981 gctgctgagg agtacgtgga ggttacgcgg gtgggggatt tccactacgt gacgggcatg

FIG. 2B

7/12

5041 accactgaca acgtaaagtg cccgtgtcag gttccggccc ccgaattctt cacagaagtg
5101 gatgggggtgc ggttgccacag gtacgtctca gcgtgcaaac ccctcctacg ggaggaggtc
5161 acattccctgg tcggggtcaa tcaatacctg gttgggtcac agtcccatg cgagcccga
5221 ccggacgtag cagtgtcac ttccatgctc accgaccctt cccacattac ggcgagacg
5281 gctaagcgta ggctggccag gggatctccc ccctccttgg ccagctcatc agctgccag
5341 ctgtctgcgc cttccttgaa ggcaacatgc actaccgtc atgactcccc ggacgtgac
5401 ctcacgagg ccaacctcct gtggcggcag gagatgggag ggaacatcac ccgctggag
5461 tcagaaaata aggtagtaat tttggactct ttcgagccgc tccaagcgga ggaggatgag
5521 aggggaagtat ccgttccggc ggagatcctg cggagggtcca ggaaattccc tcgagcgatg
5581 cccatatggg caccgccgga ttacaacctt cactgttag agtcctggaa ggaccggac
5641 tacgtccctc cagtggta caagggtgcca ttgccgctg ccaaggcccc tccgatacca
5701 cctccacgga ggaagaggac ggttgtcctg tcagaatcta ccgtgtcttc tgccttggcg
5761 gagctcgcca caaagacctt cggcagctcc gaatcgtcgg ccgtcgacag cggcacggca
5821 acggcctctc ctgaccagcc ctccgacgac ggcgacgagg gatccgacgt tgagtcgtac
5881 tcctccatgc ccccccttga gggggaaccg ggggaccccg atctcagtga cgggtcttgg
5941 tctaccgtga gcgaggaagc tagtgaggat gtcgtctgct gctcaatgtc gtatacatgg
6001 acaggcgctt tgatcacgcc atgcgctgcg gaggaagca agctgcccac caacgcgttg
6061 agcaactctt tgctgcgcca ccataacatg gtttatgcca caacatctcg cagcgcaggc
6121 ctgcggcaga agaagggtcac ctttgacaga ctgcaagtcc tggacgacca ctaccgggac
6181 gtgctcaagg agatgaaggc gaaggcgtcc acagttaagg ctaaaactcct atccgtagag
6241 gaagcctgca agctgacgcc cccacattcg gccaaatcca agtttgggta tggggcaaa
6301 gagtccgga acctatccag caaggccgtt aaccacatcc actccgtgtg gaaggacttg
6361 ctggaagaca ctgtgacacc aattgacacc accatcatgg caaaaaatga ggttttctgt
6421 gtccaaccag agaaaggagg ccgtaagcca gccgcctta tcgtattccc agatctggga
6481 gtccgtgtat gcgagaagat ggccctctat gatgtggtct ccacccttcc tcaggtcgtg
6541 atgggctcct catacggatt ccagtactct cctgggcagc gagtcgagtt cctggtgaat
6601 acctggaat caaagaaaaa ccccatgggc ttttcatatg aactcgtctg tttcgactca
6661 acggtcaccg agaacgacat ccgtgttgag gagtcaattt accaatgttg tgacttggcc
6721 cccgaagcca gacaggccat aaaatcgctc acagagcggc tttatatcgg gggtcctctg
6781 actaattcaa aagggcagaa ctgcggttat cgccggtgcc gcgcgagcgg cgtgctgacg
6841 actagctgcy gtaacaccct cacatgttac ttgaaggcct ctgcagcctg tcgagctgcy
6901 aagctccagg actgcacgat gctcgtgaac ggagacgacc ttgtcgttat ctgtgaaagc
6961 gcgggaaccc aagaggacgc ggcgagccta cgagtcttca cggaggctat gactaggtag
7021 tctgcccccc ccggggaccc gccccaacca gaatacgact tggagctgat aacatcatgt
7081 tcctccaatg tgtcggctgc ccacgatgca tcaggcaaaa ggggtgtacta cctcaccctg
7141 gatccacca cccccctgc acgggctgcy tgggaaacag ctagacacac tccagttaac
7201 tcctggctag gcaacattat catgtatgcy cccactttgt gggcaaggat gattctgatg
7261 actcacttct tctccatcct tctagcacag gagcaacttg aaaaagccct ggactgccag
7321 atctacgggg cctgttactc cattgagcca cttgacctac ctcagatcat tgaacgactc
7381 catggcctta gcgcattttc actccatagt tactctccag gtgagatcaa taggggtggc
7441 tcatgcctca ggaaacttgg ggtaccgccc ttgcgagctt ggagacaccg ggcccggaat
7501 gtccgcgcta ggcttctgct cagaggaggc agggctgcca tatgtggcaa gtacctcttc

FIG. 2C


8/12

7561 aactgggcag taaggacaaa gcttaaactc actccaatag cggccgctgg cgggctggac
7621 ttgtccagct gggtcacggc tggctacagc gggggagaca tttatcacgg cgtgtctcat
7681 gcccggcccc gctggttctg gttttgccta ctctgctcg ctgcaggaat aggcattctac
7741 ctctctccca atcgatgaag gttggggtaa aactccggc ctcttaggcc atttctctc
7801 ttttttttgt ttttttgggt ttttttggtt tttttctttt tttttttttt tttttctttt
7861 ttccttcttc cttttctctt tttttcttct ttaatggtgg ctccatctta gccctagtca
7921 cggctagctg tgaaagggtc gtgagccgca tgactgcaga gagtgtgat actggcctct
7981 ctgcagatca tgtgggtcgg catggcatct ccacctctc gcggtccgac ctgggcatcc
8041 gaaggaggac gtcgtccact cggatggcta agggagagct ctaga

FIG. 2D

9/12

A.



B.




FIG. 3

10/12




FIG. 4

11/12




FIG. 5

12/12




FIG. 6

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> HEPATITIS C VIRUS ASSAY SYSTEMS

<130> PCT 21080

<150> 60/372,847

<151> 2002-04-16

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 8732

<212> RNA

<213> Artificial Sequence

<220>

<223> HCV replicon

<400> 1

```

gccagccccc gauugggggc gacacuccac cauagaucac ucccuguga ggaacuacug 60
ucuucacgca gaaagcgucu agccauggcg uuaguaugag ugucgugcag ccuccaggac 120
ccccccuccc gggagagcca uaguggucug cggaaccggu gaguacaccg gaauugccag 180
gacgaccggg uccuucucug gaucaaccgc cucaauggccu ggagauuugg gcgugccccc 240
gcgagacugc uagccgagua guguuggguc gcgaaaggcc uugugguacu gccugauagg 300
gugcuugcga gugccccggg aggucucgua gaccgugcac caugagcacg aauccuaaac 360
cucaaagaaa aaccaaaggc cgcgccaugc acccagaaac gcuggugaaa guaaaagaug 420
cugaagauca guugggugca cgaguggguu acaucgaacu ggauucuac agcgguaaga 480
uccuugagag uuuucgcccc gaagaacguu uuccaauugau gagcacuuuu aaaguucugc 540
uauguggcgc gguauuaucc cguauugacg ccgggcaaga gcaacucggu cgccgcgauac 600
acuauucuca gaauagacuug guugaguacu caccagucac agaaaagcau cuuacggau 660
gcaugacagu aagagaauua ugcagugcug ccuaaaccu gagugauaac acugcggcc 720
acuauucugc gacaacgauc ggaggaccga agggcuuacg cgcuuuuuug cacaacaug 780
gggaucaugu aacucgccu gaucguuggg aaccggagcu gaaugaagcc auaccaaac 840
acgagcguga caccacgaug ccuguagcaa uggcaacaac guugcgcaa cuauuaacug 900
gcgaacuacu uacucuagcu ucccggcaac aaauaauga cuggauggag gcggauaaag 960
uugcaggacc acuucugcgc ucggcccuuc cggcuggcug guuuauugcu gauaaaucug 1020
gagccgguga gcgugggucu cgcgguauca uugcagcacu ggggccagau gguaagcccu 1080
cccgauucgu aguuaucua acgacgggga gucaggcaac uauggaugaa cgaaauagac 1140
agaucgcuga gauaggugcc ucacugauua agcauuggua aguuuaaaca gaccacaacg 1200
guuuuccucu agcggggauc auuccgcccc ucuccuccc ccccccuua cguuacuggc 1260
cgaagccgcu uggaauaagg ccggugugcg uuugucuaua uguuauuuuc caccuauug 1320
ccgucuuuug gcaauugag ggcccggaaa ccuggcccug ucuucugac gagcauuccu 1380
aggggucuuu cccucucgc caaaggaaug caaggucugu ugaauugcu gaaggaagca 1440
guuccucugg aagcuucuu aagacaaaca acgucuguag cgacccuuug caggcagcgg 1500
aacccccac cuggcgacag gugccucugc ggccaaaagc cacguguaua agauacaccu 1560
gcaaaggcgg cacaacccca gugccacguu gugaguugga uaguugugga aagagucaaa 1620
uggcucuccu caagcgauu caacaagggg cugaaggau cccagaaggu accccaauug 1680
augggauucg aucuggggcc ucggugcaca ugcuuuacau guguuuaguc gagguuaaaa 1740
aacgucuaag cccccgaac cacggggacg ugguuuuccu uugaaaaaca cgauauuacc 1800
auggaccggg agauggcagc aucgugcgga ggcgcgguu ucguaggucu gauacucug 1860

```

accuugucac	cgcacuaaua	gcuguuccuc	gcuaggcuca	uauggugguu	acaauuuuuu	1920
aucaccaggg	ccgaggcaca	cuugcaagug	uggauccccc	cccucaacgu	ucggggggggc	1980
cgcgaugccg	ucauccuccu	cacgugcgcg	auccacccag	agcuauucuu	uaccaucacc	2040
aaaaucuugc	ucgccauacu	cgguccacuc	auggugcucc	aggcugguau	aaccaaagug	2100
ccguacuucg	ugcgcgacac	cgggcucuuu	cgugcaugca	ugcuggugcg	gaagguugcu	2160
gggggucuuu	auguccaaau	ggcucucaug	aaguuggccg	cacugacagg	uacguacguu	2220
uaugaccauc	ucaccccacu	gcgggacugg	gcccacgcgg	gccuacgaga	ccuugcggug	2280
gcaguugagc	ccgucgucuu	cucugauaug	gagaccaagg	uuauaccug	gggggcagac	2340
accgcggcgu	guggggacau	caucuugggc	cugcccugcu	ccgcccgcag	ggggaggag	2400
auacaucugg	gaccggcaga	cagccuugaa	gggcaggggg	ggcgacuccu	cgcgccuuu	2460
acggccuacu	cccaacagac	gcgaggccua	cuuggcguc	ucaucacuag	ccucacaggc	2520
cgggacagga	accaggucga	gggggagguc	caaguggucu	ccaccgcaac	acaauuuuc	2580
cuggcgaccu	gcgucaaugg	cguguguugg	acugucuauc	auggugccgg	cucaaagacc	2640
cuugccggcc	caaagggccc	aaucacccaa	auguacacca	auguggacca	ggaccucguc	2700
ggcuggcaag	cgccccccgg	ggcgcgucuc	uugacaccau	gcaccugcgg	cagcucggac	2760
cuuuacuugg	ucacgaggca	ugccgauguc	auuccggugc	gccggcgggg	cgacagcagg	2820
gggagccuac	ucucccccag	gcccgcucuc	uacuugaagg	gcucuucggg	cgguccacug	2880
cucugccccc	cggggcacgc	ugugggcauc	uuucggcgug	ccgugugcac	ccgaggguu	2940
gcgaaggcgg	uggacuugug	acccgucgag	ucuauggaaa	ccacuauugc	guccccgguc	3000
uucacggaca	acucgucccc	uccggccgua	ccgcagacau	uccagguggc	ccaucuaac	3060
gccccuacug	guagcggcaa	gagcacuaag	gugccggcug	cguaugcagc	ccaagggau	3120
aaggugcuug	uccugaaccc	guccgucgcc	gccaccuag	guuucggggc	guauaugucu	3180
aaggcacaug	guaucgacc	uaacaucaga	accgggguaa	ggaccaucac	cacgggugcc	3240
cccaucacgu	acuccaccua	uggcaaguuu	cuugccgacg	gugguugcuc	uggggggcgcc	3300
uaugacauc	uaauauguga	ugagugccac	ucaacugacu	cgaccacuau	ccuggggcau	3360
ggcacagucc	uggaccaagc	ggagacggcu	ggagcgcgac	ucgucgugcu	cgccaccgcu	3420
acgccuccgg	gaucggucac	cgugccacau	ccaaacaucg	aggagguggc	ucuguccagc	3480
acuggagaaa	uccccuuuuu	uggcaaagcc	aucccacucg	agaccaucaa	gggggggagg	3540
caccucauuu	ucugccauuc	caagaagaaa	ugugaugagc	ucgccgcgaa	gcuguccggc	3600
cucggacuca	augcuguagc	auauuaccgg	ggccuugaug	uaucgucacu	accaacuagc	3660
ggagacguca	uugucguagc	aacggacgcu	cuaaugacgg	gcuuuaccgg	cgauuucgac	3720
ucagugaucg	acugcaauac	augugucacc	cagacagucg	acuucagccu	ggacccgacc	3780
uucaccauug	agacgacgac	cgugccacaa	gacgcggugu	cacgcucgca	gccccgaggc	3840
aggacuggua	ggggcaggau	gggcauuuac	agguuuguga	cuccaggaga	acggcccucg	3900
ggcauguucg	auuccucggg	ucugugcgag	ugcuauagac	cgggcugugc	uugguacgag	3960
cucacgcccg	ccgagaccuc	aguuaagguu	cgggcuuuac	uaaacacacc	agggguugcc	4020
gucugccagg	accaucugga	guucugggag	agcgucuuua	caggccucac	ccacauagac	4080
gcccuuuucu	ugucccagac	uaagcaggca	ggagacaacu	uccccuaccu	gguaagcauac	4140
caggcuacgg	ugugcgccag	ggcucaggcu	ccaccuccau	cgugggacca	aauguggaag	4200
ugucucauac	ggcuaaaagc	uacgcugcac	gggccaacgc	cccugcugua	uaggcuggga	4260
gccguucaaa	acgagguuac	uaccacacac	cccuaaacca	aauacaucau	ggcaugcaug	4320
ucggcgagac	uggaggucgu	cacgagcacc	ugggugcugg	uaggcggagu	ccuagcagcu	4380
cuggccgcgu	auugccugac	aacaggcagc	guggucauug	ugggcaggau	caucuugucc	4440
ggaaagccgg	ccaucauuuc	cgacagggaa	guccuuuacc	gggaguucga	ugagauggaa	4500
gagugcgccu	cacaccuccc	uuacaucgaa	cagggaugc	agcucgccga	acaauucaa	4560
cagaaggcaa	ucggguugcu	gcaaacagcc	accaagcaag	cggaggcugc	ugcucccgug	4620
guggaaucua	aguggcgagc	ccucgaagcc	uucugggcca	agcauauug	gaauuucauc	4680
agcgggauac	aaauuuuagc	aggcuugucc	acucugccug	gcaaccccg	gauagcauca	4740
cugauggcau	ucacagccuc	uauaccagc	ccgcucacca	ccaacauac	ccuccguuuu	4800
aacaucuggg	ggggauuggu	ggccgcccac	cuugcuccuc	ccagcgugc	uucugcuuuc	4860
guaggcgccg	gcaucgcugg	agcggcgugu	ggcagcauag	gccuugggaa	ggugcuugug	4920
gauauuuugg	cagguuauug	agcaggggug	gcaggcgcg	ucguggccuu	uaaggucaug	4980
agcggcgaga	ugcccuccac	cgaggaccug	guuaaccuac	ucccugcuau	ccucucccuu	5040
ggcgcccuag	ucgucggggg	cgugugcgca	gcgaucugc	gucggcacgu	ggggccaggg	5100
gagggggcug	ugcaguggau	gaaccggcug	auagcguucg	cuucgcgggg	uaaccacguc	5160

ucccccacgc	acuaugugcc	ugagagcgac	gcugcagcac	gugucacuca	gauccucucu	5220
agucuuacca	ucacucagcu	gcugaagagg	cuuccaccagu	ggaucaacga	ggacugcucc	5280
acgccaugcu	ccggcucgug	gcuaagagau	guuugggauu	ggauaugcac	gguguugacu	5340
gauuucaaga	ccuggcucca	guccaagcuc	cugccgcgau	ugccgggagu	ccccuucuuc	5400
ucaugucaac	guggguacaa	gggagucugg	cggggcgacg	gcaucaugca	aaccaccugc	5460
ccauguggag	cacagaucac	cggacaugug	aaaaacgguu	ccaugaggau	cguggggccu	5520
aggaccugua	guaacacgug	gcauggaaca	uuccccauua	acgcguacac	cacggggccc	5580
ugcacgccc	ccccggcgcc	aaauuauucu	agggcgcu	ggcggguggc	ugcugaggag	5640
uacguggagg	uuacgcgggu	ggggggaauu	cacuacguga	cgggcaugac	cacugacaac	5700
guaaagugcc	cgugacaggu	uccggccccc	gaauucuuca	cagaagugga	uggggugcgg	5760
uugcacaggu	acgcuccagc	gugcaaacc	cuccuacggg	aggaggucac	auuccugguc	5820
gggcuaauu	aaauaccggu	ugggucacag	cucccaugcg	agcccgaacc	ggacguagca	5880
gugcucacuu	ccaugcucac	cgacccucc	cacauuacgg	cggagacggc	uaagcguagg	5940
cuggccaggg	gaucuccccc	cuccuuggcc	agcucaucag	cuauccagcu	gucugcgccu	6000
uccuugaagg	caacaugcac	uacccgucac	gacuccccgg	acgcugaccu	caucgaggcc	6060
aaccuccugu	ggcgccagga	gauggggcg	aacaucaccc	gcguggaguc	agaaaaaag	6120
guaguaauuu	uggacucuuu	cgagccgcuc	caagcggagg	aggauagag	ggaaguaucc	6180
guuccggcg	agaucugcg	gagguccagg	aaauuccuc	gagcgaucc	cauauaggca	6240
cgcccgga	acaaccucc	acuguaagag	uccgguagg	acccggacua	cguccucca	6300
gugguacacg	gguguccauu	gccgcccug	aaggccccc	cgauaccacc	uccacggagg	6360
aagaggacgg	uuguccuguc	agaauucac	gugucuuuc	ccuuggcgga	gcucgccaca	6420
aagaccuucg	gcagcuccga	aucgucggcc	gucgacagcg	gcacggcaac	ggccucuccu	6480
gaccagcccu	ccgacgacgg	cgacgcggga	uccgacguug	agucguacuc	cuccaugccc	6540
ccccuugagg	gggagccggg	ggaucuccgau	cucagcgacg	ggucuuuggu	uaccguuagc	6600
gaggaggcua	gugaggacgu	cgucugcugc	ucgauguccu	acacauggac	aggcgccccc	6660
aucacgccau	gcgcugcgga	ggaaaccaag	cugcccauca	augcacugag	caacucuuug	6720
cuccgucacc	acaacuuggu	cuaugcuaca	acaucucgca	gcgcaagccu	gcggcagaag	6780
aaggucaccu	uugacagacu	gcagguccug	gacgaccacu	accgggacgu	gcucaaggag	6840
augaaaggca	aggcguccac	aguuaaggcu	aaacuucua	ccguggagga	agccuguaag	6900
cugacgcccc	cacauucggc	cagaucuaaa	uuuggcuau	gggcaaagga	cguccggaac	6960
cuauccagca	aggccguuaa	ccacauccgc	uccgugugga	aggacuugcu	ggaagacacu	7020
gagacaccaa	uugacaccac	caucauggca	aaaaauagg	uuuucugcg	ccaaccagag	7080
aagggggggc	gcaagccagc	ucgccuuau	guauucccag	auuugggggu	ucgugugugc	7140
gagaaaaugg	ccuuuacga	uguggucucc	accuccccuc	aggccgugau	gggcucuuca	7200
uacggauucc	aaauacucucc	uggacagcgg	gucgaguucc	uggugaaucc	cuggaaagcg	7260
aagaaaugcc	cuauugggcu	cgcauauag	accgcgugu	uugacucaac	ggucacugag	7320
aaugacaucc	guguugagga	gucaaucuac	caauguugug	acuuggcccc	cgaagccaga	7380
caggccaaua	ggucgcucac	agagcgccuu	uacaucgggg	gccccugac	uaauucuaaa	7440
gggcagaacu	gcggcuaucc	ccggugccgc	gcgagcggug	uacugacgac	cagcugcggu	7500
aaauaccuca	cauguuacuu	gaaggccgcu	gcggccuguc	gagcugcgaa	gcuccaggac	7560
ugcacgaugc	ucguauccgg	agacgaccuu	gucguuaucu	gugaaagcgc	ggggacccaa	7620
gaggacgagg	cgagccuacg	ggccuucacg	gaggcuaua	cuagauacuc	ugcccccccu	7680
ggggacccgc	ccaaaccaga	auacgacuug	gaguugauaa	caucaugcuc	cuccaaugug	7740
ucagucgcgc	acgaugcauc	uggcaaaaag	guguacuau	ucacccguga	ccccaccacc	7800
ccccuugcgc	gggcugcgug	ggagacagcu	agacacacuc	cagucaauuc	cuggcuaggc	7860
aacaucauca	uguauccgcc	caccuugugg	gcaaggaua	uccugaugac	ucauuucuu	7920
uccauccuuc	uagcucagga	acaacuugaa	aaagcccuag	auugucagau	cuacggggcc	7980
uguuacucca	uugagccacu	ugaccuaccu	cagaucuuuc	aacgacucca	uggccuuagc	8040
gcauuuucac	uccauaguua	cucuccaggu	gagaucaaua	ggguggcuuc	augccucagg	8100
aaacuugggg	uaccgcccuu	gcgagucugg	agacaucggg	ccagaagugu	ccgcgcuaag	8160
cuacuguccc	aggggggggag	ggcugccacu	uguggcaagu	accucuucaa	cugggcagua	8220
aggaccaagc	uccaaacucac	uccaaucccg	gcugcguccc	aguuggauuu	auccagcugg	8280
uucguugcug	guuacagcgg	gggagacaua	uauacagccc	ugucucgugc	ccgaccccg	8340
ugguucaugu	ggugccuacu	ccuacuucuu	guagggguag	gcaucuauc	acuccccaau	8400
cgaugaaggu	ugggguaaac	acuccggccu	cuaaggccau	uuccucucuu	uuuuuuguuu	8460

```

uuuugggguuu uuuuguuuuu uuucuuuuuu uuuuuuuuuu uuucuuuuuu ccuucuuuccu 8520
uuucuuuuuu uuucuuuuuu aaugguggcu ccaucuuagc ccuagucacg gcuagcugug 8580
aaagguccgu gagccgcaug acugcagaga gugcugauac uggccucucu gcagaucaug 8640
ugggucggca uggcaucucc accuccucgc gguccgaccu gggcauccga aggaggacgu 8700
cguccacucg gauggcuaag ggagagcucu ag 8732

```

<210> 2

<211> 8085

<212> DNA

<213> Artificial Sequence

<220>

<223> HCV replicon

<400> 2

```

gccagccccc gattgggggc gacactccac catagatcac tcccctgtga ggaactactg 60
tcttcacgca gaaagcgtct agccatggcg ttagtatgag tgtcgtgcag cctccaggac 120
ccccctccc gggagagcca tagtgggtctg cggaaccggt gtagtacaccg gaattgccag 180
gacgaccggg tcccttcttg gatcaaccgc ctcaatgcct ggagatttgg gcgtgcccc 240
gcgagactgc tagccgagta gtgttgggtc gcgaaaggcc ttgtggtact gcctgatagg 300
gtgcttgcca gtgccccggg aggtctcgta gaccgtgcac catgagcacg aatcctaacc 360
ctcaaagaaa aaccaaaggc cgcgccatgc acccagaaac gctggtgaaa gtaaaagatg 420
ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga 480
tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagtctctg 540
tatgtggcgc ggtattatcc cgtattgacg ccgggcaaga gcaactcggg cgccgcatac 600
actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 660
gcatgacagt aagagaatta tgcagtgtcg ccataaccat gagtataaac actgcggcca 720
acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 780
gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg 840
acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg 900
gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 960
ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg 1020
gagccggtga gcgtgggtct cgcggtatca ttgcagcact gggggccagat ggtaagccct 1080
cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 1140
agatcgctga gatagggtgc tcaactgatta agcattggta agtttaaaca gaccacaacg 1200
gtttccctct agcgggatca attccgcccc tctccctccc cccccctaa cgttactggc 1260
cgaagccgct tggaaataagg ccggtgtgctg tttgtctata tgttattttc caccatattg 1320
ccgtcttttg gcaatgtgag ggcccggaaa cctggccctg tcttcttgac gagcattcct 1380
aggggtcttt cccctctcgc caaaggaatg caaggctctgt tgaatgtcgt gaagggaagca 1440
gttccctctg aagcttcttg aagacaaaca acgtctgtag cgaccctttg caggcagcgg 1500
aacccccac ctggcgacag gtgcctctgc ggccaaaagc cacgtgtata agatacacct 1560
gcaaaggcgg cacaacccca gtgccacgtt gtgagttgga tagttgtgga aagagtcaaa 1620
tggtctcct caagcgtatt caacaagggg ctgaaggatg ccagaaggc accccattgt 1680
atgggatctg atctggggcc tcggtgcaca tgctttacat gtgttttagtc gaggttaaaa 1740
aacgtctagg ccccccgaac cacggggacg tggttttcct ttgaaaaaca cgataatacc 1800
atggcgccca ttacggccta ctcccaacag acgcgaggcc tacttggctg catcatcact 1860
agcctcacag gccgggacag gaaccaggtc gagggggagg tccaagtggc ctccaccgca 1920
acacaatctt tcctggcgac ctgcgtcaat ggcgtgtgtt ggactgtcta tcatggtgac 1980
ggctcaaaga cccttgccgg cccaaagggc ccaatcacc aaatgtacac caatgtggac 2040
caggacctcg tcggctggca agcgcctccc ggggcgcgtt ccttgacacc atgcacctgc 2100
ggcagctcgg acctttactt ggtcacgagg catgccgatg tcattccggt gcgcggcgcg 2160
ggcgacagca gggggagcct actctcccc aggcccgctc cctacttgaa gggctcttcg 2220
ggcgggtccac tgctctgccc ctccggggcac gctgtgggca tctttcgggc tgccgtgtgc 2280

```

```

acccgagggg ttgcgaaggc ggtggacttt gtaccgctcg agtctatgga aaccactatg 2340
cggtccccgg tcttcacgga caactcgccc cctccggccg taccgcagac attccagggtg 2400
gcccattctac acgcccctac tggtagcggc aagagcacta aggtgccggc tgcgtatgca 2460
gccaaggggt ataagggtgct tgtcctgaac ccgtccgctc cgcaccacct aggtttcggg 2520
gcgtatatgt ctaaggcaca tggtagcgac cctaaccatca gaaccgggggt aaggaccatc 2580
accacgggtg ccccatcac gtactccacc tatggcaagt ttcttgccga cgggtggttg 2640
tctggggggc cctatgacat cataatatgt gatgagtggc actcaactga ctcgaccact 2700
atcctgggca tcggcacagt cctggaccaaa gcggagacgg ctggagcgcg actcgtcgtg 2760
ctcgccaccg ctacgcctcc gggatcggtc accgtgccac atccaaacat cgaggagggtg 2820
gctctgtcca gcactggaga aatccccctt tatggcaaag ccattcccat cgagaccatc 2880
aagggggggg ggcacctcat tttctgccat tccaagaaga aatgtgatga gctcgccggc 2940
aagctgtccg gcctcggact caatgctgta gcatattacc ggggccttga tgtatccgtc 3000
ataccaacta gcggagacgt cattgtcgta gcaacggacg ctctaatac gggctttacc 3060
ggcgatttcg actcagtgat cgactgcaat acatgtgtca cccagacagt cgacttcagc 3120
ctggaccgga ccttcacat tgagacgacg accgtgccac aagacgggt gtcacgctcg 3180
cagcggcgag gcaggactgg taggggcagg atgggcattt acaggtttgt gactccagga 3240
gaacggccct cgggcatggt cgattcctcg gttctgtgcg agtgctatga cgcgggctgt 3300
gcttggtacg agctcacgcc cgccgagacc tcagttagggt tgcgggctta cctaaacaca 3360
ccagggttgc ccgtctgcca ggaccatcgt gacttctggg agagcgtctt tacaggcctc 3420
accacatatg acgcccattt cttgtcccag actaagcagg caggagacaa cttcccctac 3480
ctggtagcat accaggctac ggtgtgcgcc agggctcagg ctccacctcc atcgtgggac 3540
caaagtggga agtgtctcat acggctaaag cctacgctgc acgggccaac gcccctgctg 3600
tataggctgg gagccgttca aaacgagggt actaccacac accccataac caaatacatc 3660
atggcatgca tgcggctga cctggagggt gtcacgagca cctgggtgct ggtaggcgga 3720
gtcctagcag ctctggccgc gtattgcctg acaacaggca gcgtggtcat tgtgggcagg 3780
atcatcttgt ccggaagacc ggccatcatt cccgacaggg aagtccttta ccgggagttc 3840
gatgagatgg aagagtgcgc ctcacacctc cttacatcg aacagggaat gcagctcgcc 3900
gaacaattca aacagaaggc aatcgggttg atgcaaacag ccaccaagca agcggagggt 3960
gtgtctcccg tgggtggaatc caagtggcgg accctcgaag ccttctgggc gaagcatatg 4020
tggaatttca tcagcgggat acaatattta gcaggcttgt ccactctgcc tggcaacccc 4080
gcgatagcat cactgatggc attcacagcc tctatacca gcccgctcac caccacat 4140
accctctgt ttaacatcct ggggggatgg gtggccgcc aacttgctcc tccagcgct 4200
gcttctgctt tcgtaggcgc cggcatcgct ggagcggctg ttggcagcat aggccttggg 4260
aaggtgcttg tggatatttt ggcaggttat ggagcagggg tggcagggcg gctcgtggcc 4320
tttaaggtea tgagcggcga gatgccctcc accgaggacc tggttaacct actccctgt 4380
atcctctccc ctggcgccct agtcgtcggg gtcgtgtgcg cagcgatact gcgtcggcac 4440
gtggggccag gggagggggc tgtgcagtgg atgaaccggc tgatagcgtt cgcttcgctg 4500
ggtaaccacg tctcccac gcactatgtg cctgagagcg acgtgcagc acgtgtcact 4560
cagatcctct ctagtcttac catcactcag ctgctgaaga ggcttcacca gtggatcaac 4620
gaggactgct ccacgccatg ctccggctcg tggctaagag atgtttggga ttggatatgc 4680
acgggtgttg ctgatttcaa gacctggctc cagtccaagc tcctgccgcg attgccggga 4740
gtccccctct tctcatgtca acgtgggtac aagggagctt ggcgggggcg cggcatcatg 4800
caaaccacct gcccatgtgg agcacagatc accggacatg tgaaaaacgg ttccatgagg 4860
atcgtggggc ctaggacctg tagtaacacg tggcatggaa cattccccat taacgcgtac 4920
accacggggc cctgcacgcc ctccccggcg ccaaattatt ctaggcgct gtggcggtg 4980
gctgctgagg agtacgtgga ggttacgcgg ctgggggatt tccactacgt gacgggcatg 5040
accactgaca acgtaaagtgc cccgtgtcag gttccggccc ccgaattctt cacagaagtg 5100
gatgggggtg ggttgacacg gtacgttcca gcgtgcaaac cctcctacg ggaggaggtc 5160
acattcctgg tcgggctcaa tcaatacctg gttgggtcac agtccccatg cgagcccga 5220
ccggacgtag cagtgtcac ttccatgctc accgacccct cccacattac ggcgagacg 5280
gctaagcgta ggctggccag gggatctccc cctccttg ccagctcatc agctgcccag 5340
ctgtctgcgc ctcccttgaa ggcaacatgc actaccgctc atgactcccc ggacgctgac 5400
ctcatcgagg ccaacctcct gtggcggcag gagatgggag ggaacatcac ccgctggag 5460
tcagaaaata aggtagtaat tttggactct ttcgagccgc tccaagcgga ggaggatgag 5520
aggaagtat ccgttccggc ggagatcctg cggaggctca ggaaattccc tcgagcgatg 5580

```

cccatatggg cagcggcgga ttacaaccct ccactgttag agtcctggaa ggacccggac 5640
tacgtccctc cagtgggtaca cgggtgtcca ttgccgcctg ccaaggcccc tccgatacca 5700
cctccacgga ggaagaggac ggttgctctg tcagaatcta ccgtgtcttc tgccttggcg 5760
gagctcgcca caaagacctt cggcagctcc gaatcgctcg ccgtcgacag cggcacggca 5820
acggcctctc ctgaccagcc ctccgacgac ggcgacgcgg gatccgacgt tgagtcgtac 5880
tcctccatgc ccccccttga gggggaaccg ggggaccccc atctcagtga cgggtcttgg 5940
tctaccgtga gcgaggaagc tagtgaggat gtcgtctgct gctcaatgtc gtatacatgg 6000
acaggcgcct tgatcacgcc atgcgctgcg gaggaagca agctgcccc caacgcgttg 6060
agcaactctt tgctgcgcca ccataacatg gtttatgcca caacatctcg cagcgaggc 6120
ctgcggcaga agaaggtcac ctttgacata ctgcaagtcc tggacgacca ctaccgggac 6180
gtgctcaagg agatgaaggc gaaggcgctc acagttaagg ctaaaactct atccgtagag 6240
gaagcctgca agctgacgcc ccacattcg gccaaatcca agtttggcta tggggcaaag 6300
gacgtccgga acctatccag caaggccggt aaccacatcc actccgtgtg gaaggacttg 6360
ctggaagaca ctgtgacacc aattgacacc accatcatgg caaaaaatga ggttttctgt 6420
gtccaaccag agaaaggagg ccgtaagcca gcccgctta tcgtattccc agatctggga 6480
gtccgtgtat gcgagaagat ggccctctat gatgtggtct ccacccttc tcaggctctg 6540
atgggctcct catacggatt ccagtactct cctgggcagc gactcgagtt cctggtgaat 6600
acctggaat caaagaaaaa ccccatgggc ttttcatatg acactcgctg tttcgactca 6660
acggtcaccg agaacgacat ccgtgttgag gactcaattt accaatgttg tgacttggcc 6720
cccgaagcca gacaggccat aaaatcgctc acagagcggc tttatatcgg gggctcctctg 6780
actaattcaa aagggcagaa ctgcggttat cgccggtgcc gcgagcgcg cgtgctgacg 6840
actagctgcg gtaacaccct cacatgttac ttgaaggcct ctgcagcctg tcgagctgcg 6900
aagctccagg actgcacgat gctcgtgaac ggagacgacc ttgtcgttat ctgtgaaagc 6960
gcgggaaacc aagaggacgc ggcgagccta cgagtcttca cggaggctat gactaggtac 7020
tctgcccccc ccggggaccc gccccaacca gaatacgact tggagctgat aacatcatgt 7080
tcctccaatg tgcgggtcgc ccacgatgca tcaggcaaaa ggggtgtacta cctcaccctg 7140
gateccacca cccccctcgc acgggctgcg tgggaaacag ctagacacac tccagttaac 7200
tcctggctag gcaacattat catgtatgcg ccactttgt gggcaaggat gattctgatg 7260
actcacttct tctccatcct tctagcacag gagcaacttg aaaaagccct ggactgccag 7320
atctacgggg cctgttactc cattgagcca cttgacctac ctcagatcat tgaacgactc 7380
catggcctta ggcatttttc actccatagt tactctccag gtgagatcaa taggggtggc 7440
tcatgcctca ggaaacttgg ggtaccgccc ttgagagctt ggagacaccg ggcccggaa 7500
gtccgcgcta ggcttctgtc cagaggaggc agggctgcca tatgtggcaa gtacctcttc 7560
aactgggcag taaggacaaa gcttaaactc actccaatag cggccgctgg ccggctggac 7620
ttgtccagct ggttcacggc tggctacagc gggggagaca tttatcacgg cgtgtctcat 7680
gccccgcccc gctggttctg gttttgccta ctctgctcg ctgcaggaat aggcattctac 7740
ctcctcccca atcgatgaag gttggggtaa acactccggc ctcttaggcc atttctctc 7800
ttttttttgt ttttttgggt ttttttgggt tttttctttt tttttttttt tttttctttt 7860
ttccttcttc cttttctctt tttttctctt ttaatgggtg ctccatctta gccctagtca 7920
cggctagctg tgaaagggtc gtgagccgca tgactgcaga gactgctgat actggcctct 7980
ctgcagatca tgtgggtcgg catggcatct ccacctctc gcggtcggac ctgggcatcc 8040
gaaggaggac gtcgtccact cggatggcta agggagagct ctaga 8085

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/12509

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/70; G01N 33/53; C12N 9/00; C07H 21/02, 21/04
US CL : 435/5, 7.9, 183; 536/23.1, 23.2, 23.72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/5, 7.9, 183; 536/23.1, 23.2, 23.72

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN & WEST; Sequence Data bases.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 2002/0142350 A1 (KUKOLJ et al.) 03 October 2002 (03.10.2002), see the entire document, and claim 40.	1-26
Y	US 5,885,779 A (HOUGHTON et al.) 23 March 1999 (23.03.1999), see the entire patent and claims 6-7.	1-26
Y	LOHMANN et al. Mutation in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation. Journal of Virology, February 2001, Vol. 75, No. 3, pages 1437-1449.	1-26
Y	PIETSCHMANN et al. Characterization of Cell Lines Carrying Self-Replicating Hepatitis C Virus RNAs. Journal of Virology, February 2001, Vol. 75, No. 3, pages 1252-1264.	1-26
Y	LOHMANN et al. Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatitis Cell Line. Science, 2 July 1999, Vol. 285, pages 110-113.	1-26

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 August 2003 (20.08.2003)

Date of mailing of the international search report

24 SEP 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Tekchand Saidha

Telephone No. (703) 308-0196

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.